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ABSTRACT 
Alzheimer’s disease (AD) is a neurodegenerative disease that is responsible for up to 
80% of all dementia cases. Hallmarks of AD include the presence of beta-amyloid 
(Aβ) deposits and twisted strands of abnormal hyperphosphorylated tau forming 
neurofibrillary tangles (NFTs), which ultimately lead to damage and death of nerve 
cells in the brain. Symptoms of the disease include impairments in cognitive and 
functional abilities that gradually worsen as the disease progress. Finally, in advanced 
AD, patients become unable to perform basic daily activities, become more 
susceptible to infections, and ultimately die. Only five drugs are FDA-approved for 
use in AD, which only provide temporary symptomatic relief without capabilities of 
modifying the progression of the disease. Tolfenamic acid is a non-steroidal anti-
inflammatory drug that has the potential for slowing the progression of AD by 
inducing the degradation of the transcription factor specificity protein 1 (Sp1). Sp1 
regulates the expression of several AD-related genes including amyloid precursor 
protein (APP), tau and beta-site APP-cleaving enzyme 1 (BACE1).  
To investigate the ability of tolfenamic acid to cross the blood brain barrier (BBB), 
multiple approaches were utilized. In silico computational models to predict logBB 
and logPS for CNS penetration indicated that tolfenamic acid could transfer passively 
through the BBB. In addition, immobilized artificial membrane (IAM) 
chromatography using a phosphatidylcholine column was utilized for the in vitro 
determination of the brain penetration capacity factor [(KIAM/MW4)x1010] of 
tolfenamic acid. The results showed that the [(KIAM/MW4)x1010] for tolfenamic acid 
  
was 2.73 indicating its ability to cross the BBB and penetrate into the brain. Upon 
intravenous (IV) administration of tolfenamic acid to guinea pigs and mice, LC-MS 
analysis revealed the presence of tolfenamic acid in the extracted brain tissue. This in 
vivo approach was also used to estimate the brain-to-plasma ratio (Kp) for tolfenamic 
acid, which was 0.11. Thus, using in silico, in vitro and in vivo methods, we confirmed 
the ability of tolfenamic acid to cross the BBB. The study offers a guide of using 
multiple approaches to predict the ability of different compounds to penetrate the 
brain.  
Next, we investigated the ability of tolfenamic acid to attenuate the cognitive deficits 
in a transgenic mouse model of AD, namely R1.40. First, we demonstrated that 
hemizygous R1.40 mouse model exhibits spatial working and long-term memory 
deficits when tested in the Morris water maze and Y-maze. We found that short-term 
administration of tolfenamic acid for 34 days was able to reverse the observed 
cognitive deficits in hemizygous R1.40 mice. These mnemonic improvements were 
parallel to reductions in SP1 protein, APP expression and protein, and soluble and 
insoluble Aβ40-42 levels. These findings suggest that the reductions in the biochemical 
markers of AD were also accompanied by functional improvements in the treated 
mice.  
We further examined the ability of tolfenamic acid to improve spatial learning and 
memory as well as to reduce Aβ plaque pathology in old homozygous R1.40. 
Homozygous R1.40 mice exhibit cognitive deficits that are accompanied by fibrillar 
Aβ deposition in different regions of the brain by the age of 14-15 months. Our 
  
immunohistochemical results indicated that short-term tolfenamic acid treatment for 
34 days was able to produce a drastic reduction in Aβ plaque pathology. In addition, 
spatial working memory, assessed by the spontaneous alternations in the Y-maze, was 
improved by tolfenamic acid treatment. Further, we investigated if tolfenamic acid 
would improve the age-related learning and memory impairments in senescent 
C57BL/6 mice and we found that treatment with tolfenamic acid for 34 days resulted 
in improvements in the spatial reference memory functions as well. The major 
findings from these studies suggest that tolfenamic acid crosses the BBB into the 
brain, is able to decrease AD-related proteins including Aβ plaques, and is able to 
produce mnemonic functional improvements in AD transgenic mouse model and 
senescent wild type mice as well. Thus, tolfenamic acid could be proposed as a 
disease-modifying therapy for AD via its unique mechanism.    
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PREFACE 
This dissertation addresses the brain penetration of tolfenamic acid using 
multiple approaches as well as it address its effects in altering various AD-related 
pathology and improving the mnemonic deficits in a transgenic mouse model of AD 
and senescent wild type mice. It discusses the molecular biology, behavioral and 
immunohistochemical experiments used to investigate the effects of tolfenamic acid as 
a proposed disease-modifying drug candidate for AD.  
The dissertation is structured in manuscript format and it comprises three 
manuscripts. The first manuscript “The Ability of Tolfenamic Acid to Penetrate the 
Brain: A Model for Testing the Brain Disposition of Candidate Alzheimer’s Drugs 
Using Multiple Platforms” was published in 2011 in Current Alzheimer Research. The 
second manuscript “Reversal of Cognitive Deficits by Tolfenamic Acid is 
Accompanied by Reductions in Intermediates Associated with Amyloid pathology in a 
Transgenic Mouse Model of Alzheimer’s Disease” is formatted in accordance for 
submission to Neurobiology of Aging. The third manuscript “Reduction of β-Amyloid 
Deposition and Attenuation of Memory Deficits by Tolfenamic Acid” is formatted in 
accordance for submission to Alzheimer’s & Dementia.  
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The Ability of Tolfenamic Acid to Penetrate the Brain: A Model for Testing the 
Brain Disposition of Candidate Alzheimer’s Drugs Using Multiple Platforms 
By 
Gehad M. Subaiea, Bothaina H. Alansi, David A. Serra, Maged Alwan, and Nasser 
H. Zawia 
(Published in Current Alzheimer Research, 2011, 8, 860-867) 
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Abstract 
Evidence from our laboratory suggests that tolfenamic acid has a potential for slowing 
the progression of Alzheimer’s disease (AD) through lowering cortical levels of the β-
amyloid precursor protein (APP) and its pathogenic amyloid beta (Aβ) intermediates 
[1]. In this study, we examined the ability of tolfenamic acid to cross the blood brain 
barrier (BBB) by predicting its logBB and logPS values, the indexes of BBB 
permeability, using computational models. We also determined, via in vitro methods, 
the brain penetration capacity factor [(KIAM/MW4)x1010] using phosphatidylcholine 
column chromatography. The obtained logBB, logPS and (KIAM/MW4)x1010 values 
predicted that tolfenamic acid can passively transfer into the central nervous system 
(CNS). These results were validated in vivo using LC-MS analysis after administration 
of tolfenamic acid intravenously to guinea pigs and mice. The present study provides 
the first evidence of the ability of tolfenamic acid to cross the BBB and offers a 
comparative analysis of approaches used to predict the ability of compounds to 
penetrate into the brain. 
 
Keywords: Alzheimer’s disease, blood brain barrier, HPLC, mass spectrometry, 
tolfenamic acid. 
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1. Introduction 
Alzheimer’s disease (AD), a progressive neurodegenerative disease marked by 
dementia evolving till death, is characterized by plaques. These plaques are composed 
mainly of amyloid beta (Aβ) peptides that result from the cleavage of β-amyloid 
precursor protein (APP) by the enzyme β-site APP cleaving enzyme 1 (BACE1) 
followed by γ-secretase [2]. Specificity protein 1 (Sp1) is a transcription factor that is 
involved in co-activation of APP transcription and regulation of BACE1 expression 
[3, 4] and is critical for the activation of the human APP promoter [5]. Tolfenamic 
acid is a non-steroidal anti-inflammatory drug (NSAID) used in Europe for the 
treatment of migraine, and has been found to degrade the transcription factors Sp1, 
Sp3, and Sp4 proteins and thus inhibiting the growth of pancreatic tumors by 
diminishing the expression of vascular endothelial growth factor (VEGF) [6].  
Data from our lab indicate that tolfenamic acid lowers cortical Sp1 protein (SP1) 
levels and consequently APP expression and its plaque-forming Aβ products [1]. 
Compounds designed to exhibit their mode of action in the central nervous system 
(CNS) need to be assessed for their ability to cross the blood brain barrier (BBB) and 
thus we conducted several studies to examine the ability of tolfenamic acid to 
penetrate into the brain.  
There are various in silico, in vitro and in vivo models that are used in drug discovery 
for the assessment of the ability of potential drug candidates to transfer into the CNS 
[7]; however, few studies have compared the potential of these methods using a single 
compound tested across platforms. In this study, we studied the brain transfer potential 
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of tolfenamic acid using three approaches. Comparison of these approaches offers a 
guide for any study that seeks to examine brain penetration of compounds and also 
provides data relevant for future screening strategies of candidate drugs tested for AD 
therapeutics. 
First, we utilized an in silico computational model using prediction software 
developed by Advanced Chemistry Development (ACD) to predict and analyze the 
indexes of BBB permeability logBB and logPS of tolfenamic acid. Reference 
adrenergic blockers of known CNS classification such as propranolol, a compound 
known for its ability to cross the BBB [8], timolol and atenolol, both of which poorly 
cross the BBB [9, 10], were used. Second, The Immobilized Artificial Membrane 
(IAM) chromatography utilizing phosphatidylcholine column method [11] was used as 
a valid non cell-based in vitro predictor of BBB permeation. The IAM surface of the 
column resembles the lipid phase of the brain capillary endothelium and is chemically 
and thermally stable for chromatographic conditions [7]. Finally, the in silico and in 
vitro BBB permeation predictions of tolfenamic acid were validated using in vivo 
analysis where mice and guinea pigs, the two animal models we conduct our studies 
on, were administered tolfenamic acid intravenously followed by analysis of mass 
spectra data and calculating the brain-to-plasma concentration ratio, Kp, of tolfenamic 
acid after a single time point [7]. 
 
 
5 
 
2. Materials and Methods 
2.1. Materials and Standards 
Tolfenamic acid, propranolol, timolol, diclofenac sodium, potassium chloride (KCl), 
monobasic potassium phosphate (KH2PO4) and sodium chloride (NaCl) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium hydroxide 97% pellets 
and formic acid were obtained from Fisher Scientific (Fair Lawn, NJ, USA). 
Hydrochloric acid (HCl) 37%, acetonitrile, sodium phosphate dibasic dodecahydrate 
(Na2HPO4.12H2O), and water were HPLC grade from Acros Organics (Morris Plains, 
NJ, USA). Other chemicals and reagents were of analytical grade.   
2.1.1. In silico Computational Approach 
LogBB and LogPS were calculated for tolfenamic acid, propranolol, timolol and 
atenolol from values obtained through using two prediction software developed by 
ACD (Toronto, Ontario, Canada). Values used to calculate logBB were obtained from 
ACD/ChemSketch 12.0 software [12] which included octanol-water partition 
coefficient (LogP). Other brain transfer descriptors including molecular weight, 
hydrogen bond donor/acceptor number (Hd and Ha), polar surface area (PSA), free 
rotatable bond (FRB) and acid dissociation constant (pKa) were obtained from 
literature [13]. LogPS values were obtained utilizing ACD/ADME Suite software [14]. 
2.1.2. In vitro Experiment 
2.1.2.1. HPLC Conditions 
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Hitachi analytical HPLC system consisting of an L-7100 low- pressure gradient pump, 
a 4-channel degasser, an L-7200 sequential auto-sampler, and a high sensitivity diode 
array detector (190-800 nm) was used. This system is controlled by a D-7000 HPLC 
system manager software package. The HPLC apparatus was fitted with an 
analytically sized (10 cm x 4.6 mm) IAM.PC.DD2 column from Regis technologies 
(Morton Grove, IL, USA). The Dulbecco’s phosphate-buffered saline (DPBS) 
consisted of 2.7 mM KCL, 1.5 mM KH2PO4, 137 mM NaCl, and 8.1 mM Na2HPO4. 
The mobile phase consisted of acetonitrile and DPBS (20:80 v/v, pH of 5.5). Samples 
were eluted using the mobile phase with a flow rate of 0.5 ml/min at 37°C, and UV 
absorption at 210 nm. 
2.1.2.2. Selection of Reference Compounds 
Propranolol and timolol were used as reference compounds for the in vitro experiment. 
Propranolol is classified in the literature as a high brain penetration (CNS+) compound 
[8] while timolol is classified as a low brain penetration (CNS-) compound [9]. Both 
compounds were reported to show the expected CNS penetration trend when screened 
by using IAM phosphatidylcholine column chromatography [11]. 
2.1.2.3. Determination of the IAM partition coefficients  
Samples were prepared by dissolution in absolute ethanol with concentrations of 20 
µg/µl, and the IAM partition coefficients were calculated using equations from 
literature [11]. KIAM, the IAM capacity factor, was calculated from the following 
equation: 
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Where tr is the retention time of the drug and t0 is the holdup time of the column. The 
permeability of a drug through the BBB by passive diffusion (Pm) is expressed 
following correction by the molecular weight of the drug, KIAM /MWn [11]. It was 
reported that the most successful differentiation was obtained when the power function 
of KIAM /MWn was set at n = 4 at pH 5.5 [11].  
2.1.3. In Vivo Validation Using Mass Spectrometry 
2.1.3.1. Animals and Dosing 
C57BL/6 mice weighing between 25–30 g and Hartley guinea pigs weighing between 
900-1000 g were obtained from Charles River Laboratories (Wilmington, MA, USA). 
Animal experiments were carried out according to the Institutional Animal Care and 
Use Committee (IACUC) guidelines for the care and use of laboratory animals. 
Guinea pigs were grouped and anaesthetized with 20% isoflurane/PEG (v/v). One 
group was then injected with 200µl of 100 mg/kg tolfenamic acid (n=3), while the 
other group was administered 200µl vehicle (n=2) intravenously through the 
saphenous vein by the university Attending Veterinarian (AV). The animals were 
euthanized within 5-10 minutes, decapitated and their brains were collected and stored 
at -80oC. For LC/MS studies, mice were anaesthetized with 20% isoflurane/PEG (v/v) 
then injected either with 20µl of 100 mg/kg tolfenamic acid (n=3) or with vehicle 
(n=1) into the lateral tail vein by the AV. After 5 minutes, mice were anaesthetized 
and euthanized by exsanguination through cardiac puncture. Blood was collected into 
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7.5 units/ml heparin solution-treated tubes. Blood samples were then centrifuged at 
1700 x g for 10 minutes and plasma was collected and stored at -80oC. Brain tissue 
was extracted and stored in the -80oC freezer. 
2.1.3.2. Extraction Procedure and Sample Preparation 
A previously published extraction process was followed [15] and 20µl of the extract 
was injected into the mass spectrometry (MS) system. An alternate extraction method 
was also applied for brain homogenate, plasma and calibration standard samples 
analyzed by LC/MS. Each sample was treated with 4:1 0.25 M HCl to sample volume 
followed by addition of 50µl of 10 µg/ml diclofenac sodium, the internal standard 
(IS). Samples were vortexed for 1 minute followed by the addition of 2 ml ethyl 
acetate. After mixing for another minute, samples were centrifuged at 2800 x g for 10 
minutes. The organic layer was collected and evaporated to dryness under nitrogen 
stream. The residue was reconstituted in 250µl acetonitrile and filtered, then 20µl of 
each sample was injected in the LC/MS system for separation. Using a stock solution 
of 500 µg/ml tolfenamic acid in acetonitrile, brain samples were spiked with 50µl of 
10 µg/ml diclofenac sodium and with tolfenamic acid to produce the final 
concentrations of 0.05, 0.1, 0.25, 0.5, 1, 5, 10, 25 and 50 µg/ml tolfenamic acid. 
Plasma samples were spiked with 50µl of 10 µg/ml diclofenac sodium and with 
tolfenamic acid to produce the final concentrations of 1, 5, 10, 25, 50, 100 and 150 
µg/ml tolfenamic acid. 
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2.1.3.3. Apparatus and Chromatographic Conditions 
MS: Applied Biosystems Mariner® system was used which consisted of an orthogonal 
time-of-flight (TOF) mass spectrometer equipped with standard electrospray 
ionization (ESI), PE SCIECX’s Turbo Ion Spray™ (TIS) and Atmospheric Pressure 
Chemical Ionization (APCI) source. The instrument was outfitted with an integrated 
syringe pump with dual syringe rack for direct infusion into the mass spectrometer. 
Extracted samples and standards were injected directly at a flow rate of 20 µl/min and 
the negative ion mode was used for ion peak detection. 
LC-MS Method: LC unit used was an Agilent 1100 series HPLC (Agilent 
Technologies, Santa Clara, CA, USA) and separation was performed using Luna 
pentafluorophenyl propyl, PFP(2), 50 x 2.0 mm  column  with a 3 µm particle size 
(Phenomenex, Torrance, CA, USA). The Mobile phase used consisted of a mixture of 
water with 0.1% formic acid (v/v) (A) and acetonitrile with 0.1% formic acid (v/v) 
(B). Gradient elution was employed as follow: 0-15 min, 100% eluent A; 15-30 min, 
100% to 0% eluent A; 30-35 min, 100% eluent B; 35-45 min 100% to 0% eluent B; 
45-55 min 100% eluent A under a flow rate of 0.2 ml/min. Mass spectroscopy 
equipment used was QSTAR® Elite Hybrid LC/MS equipped with a high performance 
quadruple time of flight (QqTOF) mass spectrometer, a turbo ion spray, and Analyst® 
QS 2.0 software. For each sample, 20µl was injected and MS detection was conducted 
using the negative ion mode. 
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3. Results 
3.1. In Silico Computational Brain Transfer Prediction of Tolfenamic Acid 
LogBB values for tolfenamic acid and some adrenergic blockers including 
propranolol, timolol and atenolol were calculated (Table 1) using Clark’s equation 
[16]. Compounds that have logBB value of > 0.3 distribute freely to the brain 
however, compounds of logBB value of < -1 distribute poorly to the brain [17]. The 
logBB for tolfenamic acid was calculated to be 0.75 predicting its ability to distribute 
well into the brain. Propranolol had a calculated logBB of 0.1 that was less than the 
cutoff value to cross freely into the brain (0.3). However, it was much higher than -1, 
the reported value of which less than that a compound is predicted to be of poor CNS 
penetration. The calculated logBB for timolol and atenolol, both of which have poor 
CNS penetration as documented in the literature [9, 10], were -0.9 and -1.0, 
respectively, indicating their low ability to distribute into the brain. 
Another index of BBB permeability, LogPS, was obtained for tolfenamic acid and the 
three antiadrenergic drugs (Table 1) using ACD/ADME Suite software [14]. The 
program predicts compounds with logPS values less than -5 to be unable to transfer 
into the brain. The calculated LogPS values for tolfenamic acid and propranolol were -
2.1 and -2 respectively and thus both are predicted to transfer into the brain. The 
values of logPS for timolol and atenolol were -3 and -3.9 respectively which were 
close to the cutoff value of -5.0 for drugs that are predicted not to transfer into the 
brain. 
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Tolfenamic acid values of other brain transfer descriptors including octanol-water 
partition coefficient (logP), molecular weight, free rotatable bonds (FRB), hydrogen-
bond donor/acceptor number (Hd and Ha) and polar surface area (PSA) were consistent 
with the optimum values for drugs that distribute into the brain (Table 1). LogP is an 
indicator of lipophilicity; the higher the number the higher the lipophilicity. Predicted 
LogP for tolfenamic acid was 5.86 indicating it can passively cross the BBB. The 
molecular weight of tolfenamic acid is 261.7 Da which is less than 450 Da, a 
requirement for brain penetration [18]. Tolfenamic acid’s predicted FRB was 3 and 
compounds with FRB >7 are considered of low BBB permeability [16]. Compounds 
that permeate into the CNS usually have 0-4 hydrogen-bond donors and 1-5 hydrogen-
bond acceptors [19] and the drug has two hydrogen-bond donors and three hydrogen-
bond acceptors. The PSA value for tolfenamic acid was predicted to be 49.3 Å2 and 
for brain penetration, the PSA should be <90 Å2 [18]. Thus, the predicted values of 
logBB, logPS and other brain transfer descriptors strongly suggest that tolfenamic acid 
would passively distribute into the brain to a great extent. 
3.2. In vitro Brain Transfer Prediction of Tolfenamic Acid 
Using the IAM phosphotidylcholine column chromatography method described by 
Yoon et al, (2006) [11], the (KIAM/MW4) x1010 values at pH 5.5 for tolfenamic acid 
and the reference compounds, propranolol and timolol, were obtained (Table 2). 
Compounds with IAM capacity factors (KIAM/MW4)x1010 > 1.01 have high CNS 
penetration while compounds with (KIAM/MW4)x1010 < 0.64 values have low CNS 
penetration [11]. Although we had higher IAM capacity factor values than reported by 
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Yoon et al. for propranolol and timolol, the order of the values was consistent. The 
classification of CNS penetration of tolfenamic acid, propranolol and timolol based on 
their IAM capacity factor values was determined (Fig. 1). With a (KIAM/MW4)x1010 
value of 2.73, our in vitro prediction model indicated the ability of tolfenamic acid to 
transfer into the CNS. 
3.3. Presence of Tolfenamic Acid in the Brains of Guinea Pigs after IV 
Administration 
Mass spectra data of tolfenamic acid presence in the brain after intravenous 
administration in guinea pigs were the first evidence of the ability of tolfenamic acid 
to have brain disposition criteria (Fig. 2). These data suggest that tolfenamic acid’s 
presence in the brain following IV administration validates our computation and in 
vitro prediction results; however, we still need to obtain the evidence of this 
disposition of tolfenamic acid in the brain relative to the plasma concentration and 
such relativity is expressed as the brain-to-plasma ratio of tolfenamic acid.  
3.4. Determination of Brain-to-Plasma Concentration Ratio of Tolfenamic Acid 
Using the LC-MS method, the brain-to-plasma concentration ratio of a single time-
point, Kp, was determined after intravenous administration of 20µl of 100 mg/kg 
tolfenamic acid to mice via their lateral vein. Tolfenamic acid peak was identified in 
the brain (Fig. 3), confirming the earlier results of tolfenamic acid detection after IV 
administration into guinea pigs, as well as in the plasma (Fig. 4). The areas under the 
tolfenamic acid peaks in the brain and plasma were plotted versus the standard 
calibration curves of brain and plasma and were quantified using the quantification 
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wizard Analyst® QS 2.0 software. The concentration of tolfenamic acid in the brain 
was 1.21 µg/g whereas the measured concentration of tolfenamic acid in the blood was 
10.85 µg/ml and thus the Kp value calculated after 5 minutes following IV 
administration was 0.11.  
4. Discussion 
The delivery of therapeutic agents to the CNS is of great importance in CNS drug 
discovery. The BBB prevents many drugs from accessing the CNS, and hence poses a 
significant challenge for drug delivery into the CNS [20]. A survey of the 
Comprehensive Medicinal Chemistry (CMC) database showed that only 5% of over 
7,000 drugs listed were CNS active [21]. Presently, several methods are available to 
assess the potential of candidate drugs to penetrate the BBB including in silico, in 
vitro and in vivo approaches. We applied these approaches comparatively in 
assessment of the ability of tolfenamic acid to cross the BBB as a drug that we have 
demonstrated experimentally that it affects processes associated with amyloidogenesis 
in the brain [1]. 
Computational approach, compared to in vitro and in vivo methods, is cost effective 
and requires less time for analysis in brain penetration studies, however, the 
performance of such a model depends on the data input, descriptor used and modeling 
approaches [7]. The calculated LogBB value for tolfenamic acid using 
ACD/ChemSketch 12.0 software [12] showed its ability to cross the BBB and this 
prediction was consistent with its physicochemical properties (Table 1). With some 
controversy about the validity of using logBB as indicator of brain penetration [22], 
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ACD/ADME Suite software [14] was used to predict brain penetration by analyzing 
logPS value  which also indicated the ability of tolfenamic acid to cross into the CNS. 
The predicted logBB of propranolol (0.1) was much less than the actual experimental 
value (1.57) which can be explained by the presence of active transport mechanisms 
that deliver propranolol into the brain [8]. A limitation of computational models is that 
they can only predict brain penetration as a function of passive permeability and do 
not consider other factors such as efflux and influx transporters and plasma protein 
binding which can affect brain transfer of drugs. With limited number of compounds 
to design logBB and logPS models and the fact that experimental logBB and logPS 
were generated from different protocols, the computational prediction can sometimes 
be contradictory and uncertain [7]. Thus, we advanced into comparing our 
computational results with an in vitro model.  
In vitro models to determine brain penetration are developed in a way to mimic in vivo 
brain penetration, hence, there are various in vitro cell-based and non-cell-based 
models [7]. IAM chromatography technique has been experimented to predict BBB 
permeability [11, 23] with less complexity compared to other cell based models that 
require cell culture cycles. Using this method, our results showed that tolfenamic acid 
had a kIAM that reflected its ability to permeate through the BBB. The obtained kIAM 
value for tolfenamic acid was intermediate between that of propranolol and timolol. 
While it was not close to that of propranolol, it was much higher than that for timolol, 
thus we concluded that tolfenamic acid was CNS+ and that its ability to penetrate the 
brain was intermediate in nature. Although IAM chromatography is a rapid and simple 
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method which provides a promising tool for assessing BBB permeability, it has few 
limitations which include the fact that lipid molecular dynamics including lateral 
diffusion are not mimicked by IAM and that BBB permeation prediction becomes 
unreliable by IAM if the drug brain uptake is influenced by transporters or plasma 
protein binding [7, 11, 23]. However, there are numerous cellular systems that can be 
used to evaluate the influence of BBB efflux transporters including P-glycoprotein 
(PGP) and multi-drug resistant proteins (MRP) on CNS distribution of drugs. For 
examples, human colon adenocarcinoma (Caco-2) and MDR1-trasfectted Madin-
Darby Canine Kidney (MDCK) cell lines have been good tools for evaluating the BBB 
efflux transporters effect on different compounds [7]. Nevertheless, some limitations 
of using such models are valid. The fact that the in vivo BBB contains other efflux 
transporters which could exert a major effect in the overall BBB penetration and the 
fact that MDCK cell line also expresses the organic cation transporter (OCT-2) could 
lead to complications when interpreting generated data [7, 24]. Thus, the in vitro 
findings, inevitably, needed to be validated in vivo. 
Several invasive and noninvasive in vivo methods are designed for brain uptake 
experiments, which represent the most reliable validation of other models [7, 25]. 
Tolfenamic acid was present in the brain after intravenous administration in guinea 
pigs as detected by MS (Fig. 2). However, as already mentioned, we still need to 
obtain the evidence of this disposition of tolfenamic acid in the brain relative to the 
plasma concentration and such relativity is expressed as the brain-to-plasma ratio of 
tolfenamic acid. 
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The plasma-to-brain concentration ratio, the most widely used term for evaluating 
brain penetration [26], was assessed for tolfenamic acid after 5 minutes and was 
calculated to be 0.11 indicating its disposition into the brain in low levels that might 
be due to the early time point chosen. With no pharmacokinetic (PK) data available 
regarding the disposition of tolfenamic acid through the mouse body, multiple time-
point assessment and determination of area under the curve (AUC) concentration in 
brain and plasma is needed for more accurate experimental calculations of the drug 
PK. Also, Kp is heavily affected by the binding of the drug in brain and plasma [26] 
and it is known that tolfenamic acid has a very high plasma binding level up to 99.7% 
in human [27] and this could explain well the low Kp total. Thus, to avoid the effect of 
the non-specific binding, determination of the free unbound drug levels in the brain 
and plasma to generate the unbound brain-to-plasma concentration ratio, Kp,uu, could 
provide a better analysis of the brain penetration of tolfenamic acid. In addition, Kp,uu 
could describe the effect of efflux and influx transporters at the BBB on the CNS 
distribution of tolfenamic acid, if any.  
To conclude, comparative analysis of multiple approaches has predicted and validated 
the ability of tolfenamic acid to penetrate into the CNS and exert its effects that are 
manifested in lowering amyloidogenesis and treatment of migraine.  
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Table I-1. LogBB and logPS values obtained using in silico computational 
prediction software with related parameters for tolfenamic acid, propranolol, 
timolol and atenolol. 
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a Molecular weight in Dalton; b Polar Surface Area; c The number of hydrogen-bond donors; d The 
number of hydrogen-bond acceptors; e Free rotatable bond; g Octanol-water partition coefficient; h 
Equilibrium distribution between blood and brain; i Passive permeability-surface area product; j 
Equation for calculating logBB which was extracted by analyzing logBB values of a database of 179 
data points measured in rats which showed that logBB determination is strongly dependent on logP, 
PSA and FRB [16]. 
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Table I-2. Human CNS penetration evaluation of propranolol, timolol and 
tolfenamic acid from literature and calculated from the Immobilized Artificial 
Membrane (IAM) capacity factor [(KIAM/MW4)x1010] using IAM 
Chromatography [11]. 
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Compound CNS Penetrationa (KIAM/MW4)x1010 CNS Penetrationb 
Propranolol 
Timolol 
Tolfenamic Acid 
CNS+ 
CNS- 
- 
6.16 
0.73 
2.73 
CNS+ 
CNS- 
CNS+ 
a CNS penetration obtained from literature [8, 9]; b CNS penetration based on (KIAM/MW4)x1010 
values at pH 5.5; CNS+ (KIAM/MW4)x1010 > 1.01, CNS- (KIAM/MW4)x1010 < 0.64 [11]. 
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Figure I-1. Classification of CNS penetration of tolfenamic acid, propranolol and 
timolol using IAM chromatography. The IAM capacity factor [(KIAM/MW4)x1010] 
at pH 5.5 was determined. High BBB penetration (CNS+); (KIAM/MW4)x1010 > 1.01, 
low BBB penetration (CNS-); (KIAM/MW4)x1010 < 0.64, Uncertain BBB penetration; 
(KIAM/MW4)x1010 = 0.65-1. 
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Figure I-2. Mass spectra analysis of tolfenamic acid in the brain of guinea pigs 
following intravenous administration. Tolfenamic acid was administered through 
the saphenous vein (200µl of a 100 mg/kg dose) and its levels were analyzed. Ovals 
denote the desired tolfenamic acid peak with m/z of 259.8. (a) Tolfenamic acid 
standard in ethanol  (1 mg/ml); (b) Brain extract from vehicle dosed animals; (c) Brain 
extract from tolfenamic acid dosed animals; (d) Extracted tolfenamic acid peak from 
mass spectrum(c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
Figure I-3. Extracted ion count chromatogram of tolfenamic acid in the brain of 
mice following intravenous administration. Tolfenamic acid was administered 
through the lateral tail vein (20µl of a 100 mg/kg dose) and its levels in the brain were 
analyzed using the extraction and LC-MS methods described in the methods section. 
The area under tolfenamic acid peak was used for brain-to-plasma concentration ratio 
calculation. TA = Tolfenamic acid; IS = Internal standard (diclofenac sodium). 
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Figure I-4. Extracted ion count chromatogram of tolfenamic acid in the plasma 
of mice following intravenous administration. Tolfenamic acid was administered 
through the lateral tail vein (20µl of a 100 mg/kg dose) and its levels in the plasma 
were analyzed using the extraction and LC-MS methods described in the methods 
section. The area under tolfenamic acid peak was used for brain-to-plasma 
concentration ratio calculation. TA = Tolfenamic acid; IS = Internal standard 
(diclofenac sodium). 
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Abstract 
Data from our lab had shown that tolfenamic acid lowers the levels of the amyloid 
precursor protein (APP) and amyloid beta (Aβ) peptide when administered to 
C57BL/6 mice by lowering the levels of their transcriptional regulator specificity 
protein 1 (Sp1). In this study, we examined the ability of tolfenamic acid to improve 
the cognitive deficits in a transgenic mouse model of Alzheimer’s disease (AD), 
R1.40, as well as to reduce the expression of genes and the levels of proteins 
associated with AD, including SP1, APP and Aβ. Following characterization of the 
ensuing cognitive deficits in aged hemizygous R1.40 transgenic mice, we 
administered variable doses of tolfenamic acid or vehicle for thirty four days. 
Behavioral assessment of spatial learning and memory functions began on Day 15 
using the Morris water maze. Working memory was tested using the Y-maze. Results 
showed that tolfenamic acid improved both long-term spatial memory deficits as well 
as working memory in these mice. These improvements were accompanied by 
reductions in the levels of the transcriptional activator SP1, followed by decreases in 
both the mRNA and protein levels of APP, and subsequent Aβ levels. These findings 
provide evidence of the ability of tolfenamic acid to disrupt the development and the 
progression of the pathological processes associated with AD, manifested by the 
reduction of amyloidogenic proteins, and amelioration of cognitive dysfunctions. 
 
Keywords: Alzheimer’s disease; tolfenamic acid; AD transgenic mouse model; 
learning and memory; Morris water maze; Y-maze.  
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1. Introduction 
Alzheimer’s disease (AD) represents the most prevalent neurodegenerative diseases in 
the elderly. During the course of the disease, memory, cognitive performance, and 
other daily activities are all impaired as a result of extensive neuronal loss (Berg, et 
al., 1993; Braak and Braak, 1997; Nelson, et al., 2012). AD is characterized by the 
presence of neuropathological deposits consisting of extracellular senile plaques of β-
amyloid core and intraneuronal neurofibrillary tangles (NFTs) in different brain 
regions, especially in the cerebral cortex, hippocampus, subcortical nuclei and 
amygdala (Selkoe, 2001; Reddy, et al., 2010; Ballard, et al., 2011; Harrington, 2012).  
The amyloid precursor protein (APP) is processed by beta-site APP-cleaving enzyme 
1 (BACE1) and γ-secretase proteases to generate various β-amyloid (Aβ) peptide 
isoforms that can accumulate resulting in the formation of insoluble aggregates of 
amyloid plaques (Shoji, et al., 1992; Urbanc, et al., 1999; Querfurth and LaFerla, 
2010; Zhang, et al., 2012). Aβ1-40 and Aβ1-42 are the major generated isoforms with  
Aβ1-42 found to be more aggregative triggering amyloid plaque formation (Finder and 
Glockshuber, 2007). Accumulation of Aβ into amyloid plaques initiates a pathological 
cascade resulting in synaptic dysfunction and neuronal death that contribute to the 
neurodegeneration observed in AD according to the amyloid hypothesis (Hardy and 
Higgins, 1992; Selkoe, 2001).  
Over the last two decades, more evidence has been garnered as to the association 
between chronic NSAIDs intake and up to 80% reduction in risk of AD incidence, 
slowing of disease progression, and reduction of microglial activation (Andersen, et 
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al., 1995; McGeer, et al., 1996; Stewart, et al., 1997; in t' Veld, et al., 2001; Lindsay, 
et al., 2002; Zandi, et al., 2002; Etminan, et al., 2003; Vlad, et al., 2008; Cote, et al., 
2012). However, several prospective clinical trials failed to demonstrate the efficacy 
of NSAIDs in altering AD risk (in 't Veld, et al., 1998; Hayden, et al., 2007; Lyketsos, 
et al., 2007; Arvanitakis, et al., 2008). Nonetheless, the findings of the ability of a 
subset of NSAIDs to alter AD pathology and improve cognitive performance in 
murine mouse models of AD by mechanisms other than their classic cyclooxygenase 
(COX) inhibition have led to a renewed interest in these compounds as potential 
disease-modifying agents in AD (Weggen, et al., 2001; Zhou, et al., 2003; Lleo, et al., 
2004). 
No cure has been discovered for AD yet and FDA-approved drugs for use in AD 
include four cholinesterase inhibitors and one N-methyl-D-aspartate receptor 
antagonist. However, these medications are not disease-modifying therapies and they 
do not stop the progression of the disease (Ozudogru and Lippa, 2012). Current 
research focuses on interventions that target Aβ production and aggregation, and the 
production of hyperphosphorylated tau (Gotz, et al., 2012; Ozudogru and Lippa, 
2012); however, no therapeutic strategy has explored more upstream interventions at 
the transcriptional level. Specifitcity protein 1 (Sp1) co-activates the transcription of 
APP, BACE1 and tau genes (Heicklen-Klein and Ginzburg, 2000; Christensen, et al., 
2004; Docagne, et al., 2004). Consequently, changes in its levels can alter the 
downstream pathways related to amyloidogenesis (Basha, et al., 2005; Adwan, et al., 
2011) and tau (unpublished data) pathology representing an ideal target for a disease-
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modifying intervention. Tolfenamic acid, a non-steroidal anti-inflammatory drug 
(NSAID), induces the degradation of SP1 protein (Abdelrahim, et al., 2006) and data 
from our lab have shown that the treatment of wild type C57BL/6 mice with 
tolfenamic acid lowers the levels of SP1 and the expression of AD-related Sp1 target 
genes such as APP (Adwan, et al., 2011). Unpublished data from our lab also indicate 
that it can do the same to both BACE1 and tau. 
Transgenic mouse models of AD represent useful tools for elaborating mechanisms 
involved in the development and progression of AD. In addition, they allow for 
testing of new therapies in vivo to provide more accurate data to justify testing in 
human clinical trials (Hock and Lamb, 2001; Duff and Suleman, 2004). Thus, we 
decided to examine the ability of tolfenamic acid to lower AD proteins, including 
SP1, APP, and Aβ, and to examine whether such reductions are commensurate with 
an improvement in cognitive functions in a mouse model of AD. Since the 
endogenous APP promoter is largely driven by Sp1 (Docagne, et al., 2004), we 
chose to study the effects of tolfenamic acid, which degrades SP1, in R1.40 mouse 
model which utilizes the human APP promoter.  
Thus, the purpose of this experiment was to investigate the presence of memory 
deficits in the hemizygous R1.40 mice, a genomic-base transgenic mouse model that 
harbor the Swedish mutation APPK670N/M671L (Lamb, et al., 1993), and to 
examine the ability of tolfenamic acid to attenuate such deficits and to decrease AD-
related pathology. Therefore, following characterization of the learning and memory 
impairment in female hemizygous R1.40 transgenic mice, 5 and 50 mg/kg/day 
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tolfenamic acid was administered to female R1.40 mice aging between 14-21 
months via oral gavage for 34 days and the learning and memory functions were 
assessed in the Morris water maze and the Y-maze. On Day 35, mice were 
euthanized and AD associated proteins including SP1, APP and soluble and 
insoluble Aβ1–40 and Aβ1–42 were assessed in the frontal cortex, which displays 
extensive AD pathology in this animal model (Kulnane and Lamb, 2001; Lehman, et 
al., 2003). 
2. Methods 
2.1. Animal model  
The transgenic mouse model R1.40 was utilized for this study. These transgenic mice, 
B6.129-Tg(APPSw)40btla/J, were obtained from the Jackson laboratory (Bar Harbor, 
ME, USA) and colonies of hemizygous and homozygous strains were established in-
house. R1.40 is a genomic-based transgenic mouse model that was developed by 
Bruce T. Lamb, and it utilizes a yeast artificial chromosome (YAC) that contains the 
full 400 kb human APP gene and flanking sequence of approximately 250 kb to harbor 
the Swedish mutation APPK670N/M671L including the human transcriptional 
regulatory elements needed for proper spatial and temporal expression (Reaume, et al., 
1996; Lamb, et al., 1997; Hock and Lamb, 2001). The developed hemizygous R1.40 
line shows a great increase in APP and Aβ production as early as 6 months of age with 
Aβ plaque deposition occurring at 24-26 months of age compared to the wild type 
mice and it was concluded that the mnemonic deficits in R1.40 were similar to those 
observed in AD (Lamb, et al., 1999; Hock, et al., 2009). 
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2.2. Genotyping of R1.40 transgenic mice  
In order to establish transgenic mice colonies of hemizygous and homozygous R1.40, 
mice were bred and genotyped in-house at the University of Rhode Island. To ensure 
the accuracy of genotyping results, two genotyping techniques were performed: 
standard PCR followed by gel electrophoresis on 1.5% agarose gel, and the TaqMan® 
allelic discrimination assay (Applied Biosystems, Foster City, CA, USA). The 
breeding and genotyping methods were approved by University of Rhode Island 
Institutional Animal Care and Use Committee (IACUC). 
2.2.1. DNA isolation 
DNA was isolated from mouse tissue as described in the literature (Truett, et al., 
2000). In brief, tissue was obtained through tail snipping (2 mm) and was placed in 
Eppendorf tubes followed by adding 75µl of a mix of 25 mM sodium hydroxide 
(NaOH) and 0.2 mM ethylenediaminetetraacetic acid (EDTA). The tubes were placed 
in a thermocycler (Bio-Rad, Hercules, CA, USA) at 98°C for 1 hr followed by cooling 
at 15 ºC. After that, 75µl of 40 mM Tris hydrochloride (HCl) of pH 5.5 was added and 
mixed. Tubes were centrifuged at 1700 × g for three minutes and supernatants were 
collected. DNA concentration and quality was checked using the NanoDrop 2000 
Micro-Volume UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE, 
USA). 
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2.2.2. Standard PCR and agarose gel electrophoresis 
Standard PCR genotyping method for R1.40 mice was performed as provided by the 
Jackson laboratory (Bar Harbor, ME, USA). The primer pairs for the APP transgene 
used were: IMR6938 (5'-CTT CAC TCG TTC TCA TTC TCT TCC A-3') and 
IMR6939 (5'-GCG TTT TTA TCC GCA TTT CGT TTT T-3'). Each reaction 
consisted of a mixture of 10µl TaqMan® genotyping master mix (Applied Biosystems, 
Foster City, CA, USA), 2µl of each primer and 2µl DNA from test samples. PCR 
amplification step was performed using a thermocycler (Bio-Rad, Hercules, CA, USA) 
as follows: 94°C for 3 min and then 35 cycles of 94°C for 30 sec, 65°C for 30 sec and 
72°C for 30 sec, and then at 72°C for 2 min. Bands were then separated by gel 
electrophoresis on 1.5% agarose gels containing ethidium bromide and bands were 
visualized using Typhoon™ 9410 Variable Mode Imager (GE Healthcare, Piscataway, 
NJ, USA). 
2.2.3. TaqMan® allelic discrimination assay  
To distinguish between hemizyougs and homozygous R1.40 YAC APP and WT, 
TaqMan® allelic discrimination assay was performed. SNP genotyping assay, 
catalogue: M_23312848_20, containing the context sequence ([VIC/FAM]): TAC 
TGC TCA CTC TTT TAA CAA ACA T[A/G]G GAA ACT AAT GAA ATG GTA 
TCA CAA was obtained from ABI (Applied Biosystems, Carlsbad, CA, USA) and the 
assay was performed according to ABI protocol. Briefly, each reaction consisted of 
6.25µl 2× TaqMan® genotyping master mix (Applied Biosystems, Foster City, CA, 
USA), 0.625µl 20× SNP genotyping assay mix, 3.125µl RNase free water and 2.5µl 
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genomic DNA from test samples. The pre-read run and PCR amplification were 
conducted in a 7500 Real-Time PCR System following ABI standard protocol, which 
was 95°C for 10 min followed by 40 cycles of 92°C for 15 sec and 60°C for 1 min. 
Following the post-read run, results were analyzed using the sequence detection 
software (SDS, version 1.3) from ABI and the allelic discrimination scatter plots were 
automatically generated.  
2.3. Assessment of cognitive deficits in hemizygous R1.40 transgenic mice  
In order to characterize memory and cognitive deficits in the hemizygous R1.40 
transgenic mouse model, behavioral testing in mazes that are dependent on the 
integrity of the hippocampus and brain cortex was conducted using the Morris water 
maze and spontaneous alternations in the Y-maze. Female hemizygous APP transgenic 
(n=19) and female control wild type (n=18) groups of ages ranging between 9-20 
months were used.  
2.3.1. Morris water maze 
We have tested the mice in the hidden version of the Morris water maze. In this task, 
the mice had to locate the hidden platform by learning multiple spatial relationships 
between the platform and the distal extra-maze cues (Vorhees and Williams, 2006; 
Gulinello, et al., 2009; Laczo, et al., 2009). The apparatus consisted of a white 48” 
diameter pool that is 30” in height and was filled with water to a depth of 14”. The 
water was kept opaque by the addition of white non-toxic liquid washable paint. The 
pool was surrounded by distinct fixed visual cues that the animals used to navigate 
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to reach the escape platform. A clear Plexiglas platform square of 10 cm was kept 
submerged 0.5 cm below the surface of the water. The temperature of the water was 
kept 25 ±2°C during all procedures in the water maze. On Day 15 of tolfenamic acid 
administration, mice received a habituation trial in which they were allowed to swim 
freely for 60 sec. On the following day and for a total of 8 days, mice received 
training sessions of 3 trials daily. The starting position for each trial was randomly 
assigned between the four possible positions while the platform position was fixed 
in each trial. Each animal was allowed to swim until they found the immersed 
hidden platform or for a maximum duration of 60 sec. If the mouse failed to locate 
the platform, it would be gently guided to sit on the platform for a maximum 
duration of 30 sec. Mice were also left to sit on the platform for a maximum of 10 
sec upon successful trial. Upon conducting the 8 acquisition sessions, probe trials for 
up to 60 sec on Day 1 and Day 11 following the last day of training were performed 
to assess the long term memory retention by studying the preference of the mice for  
the correct quadrant that previously contained the hidden platform. The swim paths 
and latencies to locate the platform were videotaped and tracked with a 
computerized video tracking system (ObjectScan, Clever Sys. Inc., Reston, VA, 
USA) and the resultant data were analyzed. 
2.3.2. Spontaneous alternations in the Y-maze  
The spontaneous alternation ratio, defined as the percentage of the number of arm 
entries, different from the previous two entries, divided by the total arm entries 
minus two (King, et al., 1999; Hock, et al., 2009) was measured. Testing was 
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conducted in a white Y-maze with arms that were 12” (long) by 3” (wide) with 8” 
height walls. Mice were placed into one of the Y-maze arms and were left to explore 
the maze freely for 5 minutes. After each trial, the maze was cleaned with 70% 
ethanol. Y-maze trials were videotaped and tracked with a computerized video 
tracking system (ObjectScan, Clever Sys. Inc., Reston, VA, USA) and the data were 
analyzed. 
2.4. Animal exposure to tolfenamic acid and behavioral testing 
Tolfenamic acid was obtained from Sigma Aldrich (St. Louis, MO, USA) and female 
hemizygous APP YAC transgenic mice aging between 14-21 months were used to 
examine the ability of tolfenamic acid to reduce the amyloidogenic load and to 
improve the learning and memory deficits of the mice. The animals were divided into 
three groups of similar age variation and were administered tolfenamic acid daily via 
oral gavage for 34 days; one group was administered 5 mg/kg/day tolfenamic acid in 
corn oil (n=6); the second group was administered 50 mg/kg/day tolfenamic acid in 
corn oil (n=7) and the third group was administered corn oil, the vehicle, (n=6). After 
14 days of daily dosing, mice were tested in the Morris water maze as described in 
section 2.3.1. On Day 33, mice were tested for spontaneous alternations in Y-maze as 
described in section 2.3.2. Finally, on Day 35, mice were euthanized and brain tissue 
was extracted, dissected and stored at -80°C. Figure 1 provides a timeline for the 
experimental events involved in this study of drug administration and behavioral 
assessment. 
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2.5. Protein extraction and Western blot analysis 
Brain cortices were homogenized with RIPA lysis buffer containing 10 mM Tris-HCl 
[pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, and 0.1% 
protease inhibitor cocktail. The homogenates were centrifuged at 10,000 × g for 10 
minutes at 4°C and supernatants were collected. Protein levels were determined using 
the BCA kit (Pierce Biotechnology Inc., Rockford, IL, USA). Forty µg of total protein 
was separated on 8% SDS polyacrylamide gel and then transferred onto 
polyvinylidiene diflouride (PVDF) membranes (GE Healthcare, Piscataway, NJ, 
USA). Membranes were blocked using 5% non-fat milk in TBST (Tris buffered saline 
+ 0.5% Tween-20, pH 7.4) for 1 hr. After that, membranes were incubated overnight 
at 4°C with the specific antibody diluted in TBST for 1 hr (1:2000 dilution of 6E10 for 
APP (Covance Research Products Inc., Dedham, MA, USA) and 1:500 dilution of 1C6 
for SP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing 
membranes 4 times with TBST, membranes were incubated for one hour with the 
appropriate anti-mouse IRDye® 680 (Li-Cor Bioscience, Lincoln, NE, USA) (1:5000) 
at room temperature. After washing the membranes twice with TBST, the images were 
developed using the Li-Cor Odyssey infrared imaging system (Li-Cor Bioscience, 
Lincoln, NE, USA). The membranes were also re-probed for β-actin (Sigma Aldrich, 
St. Louis, MO, USA) at a dilution of 1:2500 in TBST to obtain the APP/β-Actin ratio. 
The intensities of the obtained Western blot bands were determined using Odyssey 
V1.2 software (Li-Cor Bioscience, Lincoln, NE, USA). 
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2.6. RNA isolation, synthesis of cDNA and quantitative Real-Time PCR 
RNA was isolated from cortical tissue following the TRIzol® Reagent method 
(Invitrogen, Carlsbad, CA, USA), checked for integrity using NanoDrop 2000 Micro-
Volume UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and 
gel electrophoresis. RNA was reverse transcribed to cDNA using the iScriptTM Select 
cDNA Synthesis Kit following manufacturer’s instructions (Bio-Rad, Hercules, CA, 
USA). About 1000ng of RNA was diluted to 19.5µl with nuclease free water, then 3µl 
Oligo (dT) mix, 6µl 5x iScript Select reaction mix, and 1.5µl of iScript reverse 
transcriptase was added. Samples were incubated at 42°C for 90 min then at 85°C for 
5 min to terminate the reaction. All incubations were conducted using MJ Research 
MiniCyclerTM PTC-150 (Bio-Rad, Hercules, CA, USA). Primer pairs for Sp1, APP 
and β-actin were obtained from Invitrogen (Carlsbad, CA, USA) as follows: Sp1 
sense: 5’-CAA GCC CAA ACA ATC ACC TT-3’, and antisense, 5’-CAA TGG GTG 
TGA GAG TGG TG-3’; APP sense: 5’-TGC AGC AGA ACG GAT ATG AG-3’, and 
antisense: 5’-ACA CCG ATG GGT AGT GAA GC-3’; β-actin sense: 5’-TGT TAC 
CAA CTG GGA CGA CA-3’, and antisense: 5’-TCT CAG CTG TGG TGG TGA 
AG-3’. Each Real-Time PCR reaction mix contained 2µl of cDNA, 1µl of each 
primer, 8.5µl nuclease free water and 12.5µl SYBR® Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA). Real-Time PCR was conducted using 7500 Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA) following the 
standard protocol: 50°C for 2 min followed by 95°C for 10 min, then 40 cycles of 
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95°C for 15 sec and 60°C for 1 min. Results were analyzed using SDS software and 
expression data were reported relative to β-actin mRNA using the 2-∆∆Ct method. 
2.7. ELISA Aβ1–40 and Aβ1–42 assay  
Amyloid beta (Aβ) levels both soluble and insoluble fractions were determined by 
enzyme-linked immunosorbent assay (ELISA) using human Aβ1–40 and Aβ1–42 assay 
IBL kits JP27713 and JP27711 (Immuno-Biological Laboratories, Gunma, Japan). 
These kits are solid-phase sandwich ELISA with two types of highly specific 
antibodies that are 100% reactive with mouse Aβ1-40 with a sensitivity of 5.00 pg/mL 
(JP27713), and 70% reactive with mouse Aβ1-42 with 4.03 pg/mL sensitivity 
(JP27711). The assay conditions were followed according to a method described in the 
literature (Morishima-Kawashima, et al., 2000) with slight modifications. Brain tissue 
was homogenized in Tris-saline (TS) [50 mM Tris-HCl buffer, pH 7.4, 150 mM NaCl, 
1 µg/ml TLCK (N-α-p-tosyl-L-lysine chloromethyl ketone), 1µg/ml antipain, 0.5 mM 
DIFP (diisopropyl fluorophosphates), 0.5 mM PMSF, 0.1% protease inhibitor 
mixture] and centrifuged at 100,000 × g for 20 min at 4°C. The supernatant was 
collected as the soluble fraction of Aβ. The pellet was resuspended in 4 vol of TS and 
centrifuged at 70,000 × g for 20 min at 4°C. The resultant pellet was dissolved in 
500µl of 6 M guanidine-HCl (in 50mM Tris buffer, pH 7.6), incubated at room 
temperature for 30 min, and centrifuged at 70,000 × g for 20 min at 4°C. The resultant 
supernatant was collected as the insoluble fraction of Aβ and diluted by enzyme 
immunoassay (EIA) buffer (supplied with the kit) to 12× to reduce sample guanidine-
HCl concentration. Protein levels were determined using the BCA kit (Pierce 
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Biotechnology Inc., Rockford, IL, USA). Aliquots (100µg of protein in 100µl of EIA 
buffer) and assay standards were added to 96-well plates [pre-coated with anti-human 
Aβ1-40 and Aβ1-42] and were incubated overnight at 4°C. The wells were washed seven 
times with EIA buffer. Then, 100µl of labeled antibody was added to each well 
containing sample or standard and incubated at 4°C for 1 hr. The wells were washed 
nine times with EIA buffer followed by the addition of 100µl of tetramethylbenzidine 
(TMB) buffer, and incubated in the dark for 30 min at room temperature. The reaction 
was stopped by adding 100µl of 1N H2SO4, and the colorimetric absorption was 
measured at 450 nm using Spectra Max UV/Vis Spectrometer (GMI Inc., Ramsey, 
MN, USA). The levels of Aβ in the test samples were calculated relative to the 
standard curve generated on each plate. 
2.8. Statistical analysis  
Biochemical data are expressed as the mean ± the standard error of the mean (SEM). 
The significance of difference in behavioral performance in the Morris water maze 
daily training sessions between the hemizygous R1.40 and the wild type groups was 
determined using repeated measure analysis of variance (ANOVA) while probe 
trails difference between both groups was determined by two-tailed student t-test. 
The significance of difference between different treatment groups was determined 
by repeated measure ANOVA and Tukey-Kramer multiple comparison post-hoc 
test. All statistical analyses were conducted using GraphPad InStat 3 software 
(GraphPad Software, La Jolla, CA, USA). Probability (p) value of <0.05 was 
considered statistically significant. 
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3. Results 
3.1. Genotyping of R1.40 mice 
The primer pairs IMR6938 and IMR6938 amplified the 84 bp PCR product from the 
mutant human APP whereas no PCR product was expected from the non-transgenic 
mice (Fig. 2A). Thus, the detected bands at 84 bp in agarose gels represent either a 
hemizygous or homozygous mutant APP alleles. Allelic discrimination scatter plots 
were generated showing three cluster groups classifying the unknown samples as 
hemizygous APP mice having both allele A and allele G, and as homozygous APP 
mice having allele G or wild type mice having only Allele A (Fig. 2B). Thus, by 
allelic discrimination assay we were able to identify hemizygous and homozygous 
transgenic APP mice, and the wild type mice as well.   
3.2. Hemizygous R1.40 exhibits cognitive impairments when tested in Morris water 
maze and in the Y-maze 
Spatial navigation in the Morris water maze is one type of the tests used to assess 
long-term memory functions, which is usually impaired in AD. In the daily sessions 
that consisted of three trials per day for a total of eight days, repeated measure 
ANOVA indicated no significant difference in the performance in this task, assessed 
by measuring escape latency, between the transgenic group and the control wild type 
mice (F(7,245) = 0.924, p ≥ 0.05) (Fig.3A). However, probe trials that assessed the 
percent time in the correct quadrant that contained the hidden platform showed that 
as the retention delay increased from Day 1 following the last day of the daily 
training sessions to Day 11, the transgenic mice exhibited memory impairment as 
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they failed to remember the location of the hidden platform. As shown in Fig. 3B, 
probe trial in Day 1 following the last day of daily training sessions showed no 
significant difference between both groups (p > 0.1). However, after a longer delay 
on Day 11 following the last day of daily trainings sessions, the hemizygous R1.40 
transgenic mice significantly spent less time (M = 23% ; SEM = 1.99%) compared 
to the control wild type mice (M = 29.8% ; SEM= 2.58%), p = 0.045 (Fig. 3B).  
Working memory function was assessed by measuring the spontaneous alternations 
in the Y-maze defined as the percentage of the number of arm entries, different from 
the previous two entries, divided by the total arm entries minus two. This task is 
based on the innate nature of the mice to visit arms that have not been recently 
visited (King, et al., 1999; Hock, et al., 2009). Results revealed that hemizygous 
transgenic R1.40 mice exhibited impaired working memory function as they had a 
significantly lower spontaneous alternation ratio (M = 0.413 ; SEM = 0.021) than 
the control wild type mice (M = 0.496 ; SEM = 0.019), p = 0.0047 (Fig. 4). 
3.3. Treatment with tolfenamic acid reverses the cognitive deficits in hemizygous 
R1.40 mouse model  
We have determined the presence of impaired behavioral performance in the 
hemizygous R1.40 mice manifested by a decline in the long-term memory and the 
working memory functions as identified by the retention of the spatial location of the 
platform in the Morris water maze and the spontaneous alternations in the Y-maze, 
respectively.  
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Thus, we examined the ability of a tolfenamic acid treatment of 5 and 50 mg/kg/day to 
attenuate such learning and memory deficits in groups of female hemizygous R1.40 
transgenic mice aging between 14-21 months. In the Morris water maze task, escape 
latency among the treatment and the vehicle groups showed no significant difference 
in daily learning acquisition (Fig. 5A). However, ANOVA analysis indicated an 
improvement in long-term memory retention in Day 11 probe trial (F(2,15) = 4.145, p 
= 0.0369) (Fig. 5B). The Tukey-Kramer HSD post-hoc test showed that mice group 
treated with 50 mg/kg/day tolfenamic acid had a significant improvement (HSD = 
3.12, p < 0.05) while the treatment with 5 mg/kg/day failed to reach significance 
(HSD = 0.71 p ≥ 0.5) (Fig. 5B). 
Results from the ANOVA analysis of the spontaneous alternation ratio in the Y-maze 
showed a significant improvement in working memory (F(2,15) = 4.479, p = 0.0298) 
(Fig. 6). The Tukey-Kramer HSD post-hoc test revealed a significant improvement 
with tolfenamic acid treatment of 50 mg/kg/day (HSD = 4.139, p < 0.05), however, 
treatment with 5 mg/kg/day did not reach significance (HSD = 1.30, p ≥ 0.05) (Fig. 6) 
3.4. Tolfenamic acid treatment lowers SP1 protein without altering Sp1 gene 
expression 
The protein expressions of cortical SP1 normalized to β-actin was analyzed by 
Western blot following treatment with 5 and 50 mg/kg/day for 34 days or with vehicle. 
Results analyzed with ANOVA revealed a significant difference in SP1 protein levels 
(F(2.11) = 8.747, p = 0.0053) (Fig. 7A). The Tukey-Kramer HSD post-hoc test 
indicated a significant decrease of SP1 after treatment with 5 mg/kg/day tolfenamic 
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acid (HSD = 4.145, p < 0.05, % change = - 43%) and after treatment with 50 
mg/kg/day tolfenamic acid (HSD = 5.712, p < 0.01, % change = - 52%) (Fig. 7A).  
Gene expression of Sp1 was evaluated for the different treatment groups as well. 
Analysis of Sp1 mRNA levels showed that treatment with tolfenamic acid did not alter 
the gene expression of Sp1 (F(2,16) = 0.082, p = 0.922) indicating that the decrease in 
SP1 protein levels is not due to a change in its de novo gene expression (Fig. 7B).  
3.5. Reduction of APP protein and mRNA following treatment with tolfenamic acid 
The protein expressions of cortical APP normalized to β-actin was analyzed by 
Western blot following treatment with 5 and 50 mg/kg/day for 34 days or with vehicle. 
Results analyzed with ANOVA revealed that APP levels were lowered significantly 
(F(2,9) = 8.377, p = 0.009) (Fig. 8A). The Tukey-Kramer HSD post-hoc test indicated 
a significant decrease in APP after treatment with 5 mg/kg/day tolfenamic acid (HSD 
= 4.877, p < 0.05, % change = - 30.3%) and after treatment with 50 mg/kg/day 
tolfenamic acid (HSD = 5.139, p < 0.05, % change = - 32.5%) (Fig. 8A).  
In addition to analysis of APP protein levels, APP gene expression was evaluated for 
the different treatment groups by Real-Time PCR. ANOVA analysis of APP mRNA 
levels revealed a significant decrease in APP gene expression (F(2,15) = 5.238, p = 
0.019) (Fig. 8B). The Tukey-Kramer HSD post-hoc test indicated a significant 
decrease of APP mRNA after treatment with 5 mg/kg/day tolfenamic acid (HSD = 
3.885, p < 0.05, % change = - 50.3%) and after treatment with 50 mg/kg/day 
tolfenamic acid (HSD = 4.039, p < 0.05, % change = - 52.3%) (Fig. 8B).  
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3.6. Tolfenamic acid lowers both soluble and insoluble Aβ1–40 and Aβ1–42 levels  
We measured the levels of cortical Aβ1–40 and Aβ1–42 levels in the Tris-saline-soluble 
and in the insoluble fraction using IBL ELISA kits as described in literature 
(Morishima-Kawashima, et al., 2000). ANOVA analysis showed that there was a 
significant reduction in soluble Aβ1–40 fraction (F(2,14) = 3.89, p = 0.04) (Fig. 9A) and 
the insoluble Aβ1–40 fraction (F(2,14) = 4.95, p = 0.02) (Fig. 9B). The Tukey-Kramer 
HSD post-hoc test indicated a significant decrease in soluble Aβ1–40 after treatment 
with 50 mg/kg/day (HSD = 3.91, p < 0.05, % change = - 30.1%), however, the 
lowering of soluble Aβ1–40 after treatment with 5 mg/kg/day did not reach significance 
(HSD = 2.55, p ≥ 0.05, % change = - 21.3%) (Fig. 9A). Multiple group comparison 
showed a significant decrease in the insoluble Aβ1–40 fraction after treatment with 5 
mg/kg/day (HSD = 3.73, p < 0.05, % change = - 35.2%) and after treatment with 50 
mg/kg/day tolfenamic acid (HSD = 3.97, p < 0.05, % change = - 37.4%) (Fig. 9B). 
Also, ANOVA analysis showed a significant decrease in soluble Aβ1–42 fraction 
(F(2,14) = 6.174, p = 0.012) (Fig. 9C) and the insoluble Aβ1–42 fraction (F(2,14) = 
6.343, p = 0.011) (Fig. 9D). The Tukey-Kramer HSD post-hoc test indicated a 
significant decrease in soluble Aβ1–42 after tolfenamic acid treatment with 5 mg/kg/day 
(HSD = 4.18, p < 0.05, % change = - 22.3%) and after treatment with 50 mg/kg/day 
(HSD = 4.518, p < 0.05, % change = - 24.9%) (Fig. 9C). Multiple group comparison 
showed a significant decrease in the insoluble Aβ1–42 fraction after treatment with 5 
mg/kg/day (HSD = 4.72, p < 0.05, % change = - 31.8%) and after treatment with 50 
mg/kg/day (HSD = 4.79, p < 0.05, % change = - 37.7%) (Fig. 9D). 
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We also observed that 5 and 50 mg/kg/day tolfenamic acid treatment reduced total 
Aβ1-42/Aβ1-40 ratio -16.3% and -19.9%, respectively. However, this reduction in Aβ1-42 
/Aβ1-40 did not reach statistical significance (F(2.14) = 1.788 , p = 0.203). 
4. Discussion 
Several mechanisms have been proposed to explain how NSAIDs could exert their 
effects on AD independent of their COX inhibitory pathways. Certain NSAIDs 
including indomethacin, fulfinamic acid, ibuprofen and fenoprofen are agonists for the 
nuclear transcriptional regulator peroxisome proliferator-activated receptor-γ (PPARγ) 
(Lehmann, et al., 1997; Heneka, et al., 2011) that has been reported to be reduced in 
AD brains (Sastre, et al., 2006). PPARγ activation results in a reduction in the levels 
of Aβ-induced proinflammatory response of microglia and monocytes, and promotes 
Aβ clearance by astrocytes and microglia (Matsuo, et al., 1996; Combs, et al., 2000; 
Daynes and Jones, 2002; Yue and Mazzone, 2009; Mandrekar-Colucci, et al., 2012). 
In addition, a PPARγ responsive element (PPRE) has been identified in the BACE1 
gene promoter that is repressed by PPARγ binding resulting in a decrease in BACE1 
expression (Sastre, et al., 2003; Sastre, et al., 2006). Weggen et al., reported that a 
subset of NSAIDs specifically lowers Aβ1-42 that was accompanied by a parallel 
increase in Aβ1-38 suggesting a minor γ-secretase modulatory effect without alteration 
of the Notch pathway (Weggen, et al., 2001). The specific Aβ1-42 inhibition by that 
subset of NSAIDs was further studied by Zhou et al., and concluded that the 
involvement of Rho-Rock pathway in regulating APP processing, and inhibition of 
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Rho activity by specific NSAIDs could preferentially reduce Aβ1-42 (Zhou, et al., 
2003).  
Tolfenamic acid, of all other NSAIDs, has the unique mechanism of inducing the 
proteasome dependent degradation of SP transcription factors including SP1, SP3 and 
SP4 and thereby, decreasing the expression of vascular endothelial growth factors 
(VEGF) (Abdelrahim, et al., 2006), which is involved in tumor progression and 
metastases. Because of its SP degradation effects, tolfenamic acid has been studied 
and research has confirmed its antitumor effects (Abdelrahim, et al., 2006; Konduri, et 
al., 2009; Basha, et al., 2011; Colon, et al., 2011).  
Sp1 involvement in AD has been researched and it was found that its expression was 
elevated in the frontal cortex of human AD brains as well as in the brains of transgenic 
mouse models of AD (Santpere, et al., 2006; Citron, et al., 2008). The elevation of Sp1 
was accompanied by an increase in COX-2, another Sp1 target gene, suggesting 
interplay between inflammatory processes and Sp1 driven gene expression (Citron, et 
al., 2008). Sp1 binds to 5’-GGGGCGGGGC-rich promoter genes such as APP and 
BACE1 genes, which are involved in AD pathology, and Sp1 overexpression leads to 
induction of their protein expression (Cai, et al., 2001; Christensen, et al., 2004; 
Citron, et al., 2008). We have reported that silencing of Sp1 gene by siRNA resulted in 
70% decrease in the responsiveness of the human APP promoter (Basha, et al., 2005). 
Also, we have shown the co-localization of APP, Sp1 and Aβ in various regions of the 
brain (Brock, et al., 2008). Thus, we had proposed the hypothesis that tolfenamic acid 
could interrupt the de novo synthesis of APP and consequently, alter the downstream 
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levels of Aβ. This hypothesis was confirmed when oral treatment with tolfenamic acid 
resulted in degradation of SP1 that was accompanied by a reduction in cortical and 
hippocampal APP gene expression and protein and Aβ peptide levels (Adwan, et al., 
2011). This was further supported by measurements which demonstrated the presence 
of tolfenamic acid in the brain following IV administration (Subaiea, et al., 2011). 
In the present study, we demonstrate that hemizygous R1.40 transgenic mice exhibit 
cognitive deficits upon assessment of their working memory and long-term memory 
retention even before the reported age at which hemizygous R1.40 start to show 
extensive β-amyloid deposition (Lamb et al., 1999). Spatial learning was assessed in 
the hidden version of the Morris water maze and we found that the transgenic mice 
were able to learn escaping to the hidden platform in the daily training sessions (Fig. 
3A). However, they exhibited memory retention impairments in the probe trials as 
they failed to memorize the spatial location of the hidden platform with increased 
delay (Fig. 3B, Day 11). In addition, working memory assessed in the Y-maze was 
impaired in these mice with numerous alternation errors and a lowered alternation 
ratio compared to the WT control group (Fig. 4). It has been proposed that recent 
spatial memory is hippocampal-dependent, while remote spatial memory is dependent 
on the integrity of the medial prefrontal cortex (King, et al., 1999; Frankland and 
Bontempi, 2005; Teixeira, et al., 2006). In turn, working memory assessed in the Y-
maze is hippocampal and cortical-dependent (Lalonde, 2002). That, together with the 
findings that the R1.40 mouse model exhibits extensive amyloid deposition in the 
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cortical region compared to that observed in the hippocampal formation (Hock, et al., 
2009), may explain the observed results. 
We report here that short-term tolfenamic acid administration was able to improve the 
mnemonic deficits observed in hemizygous R1.40. We found that 50 mg/kg/day 
tolfenamic acid was able to reverse the long-term memory retention deficits seen in 
delayed probe trial of the Morris water maze experiment (Fig. 5B). In addition, the 50 
mg/kg/day treatment group showed significant improvement in the Y-maze with less 
error in spontaneous alternations (Fig. 6). However, the short-term treatment with 5 
mg/kg/day showed only modest effects in reversing the memory deficits in the mice. 
Analysis of amyloid pathology markers indicated that both treatment regimens, 5 and 
50 mg/kg/day, were able to significantly lower the protein level of SP1 without 
altering it gene expression (Fig. 7A and 7B), similar to our previous findings in the 
C57BL/6 treated with tolfenamic acid (Adwan, et al., 2011). In addition, both 
tolfenamic acid doses significantly reduced the protein levels of APP and its gene 
expression (Fig. 8A and 8B). Furthermore, levels of the soluble and insoluble Aβ1–40 
and Aβ1–42 were reduced by tolfenamic acid with a trend toward lowering the insoluble 
fractions of Aβ more than that of the soluble fraction. It is possible that tolfenamic 
acid may aid in clearance of insoluble Aβ by a PPARγ activation, however, it is not 
clear yet if tolfenamic acid activates PPARγ as certain other NSAIDs do.  
While tolfenamic acid was effective in lowering the amyloidogenic proteins with both 
doses, we observed dose-dependent improvement in the cognitive deficits. Whether 
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longer period of treatment with low dose tolfenamic acid could result in significant 
improvements in cognitive function is yet to be studied.  
In conclusion, tolfenamic acid is unique among NSAIDs in its ability to inhibit Sp1 
and thus interrupt APP de novo synthesis and its Aβ products. In this study, we 
demonstrated that short-term administration of tolfenamic acid for 34 days reversed 
the cognitive deficits in hemizygous R1.40 transgenic mice. Consistent with our 
previous published findings in C57BL/6 mice, SP1, the amyloidogenic levels of APP 
and soluble and insoluble Aβ1–40 and Aβ1–42 were markedly lowered by tolfenamic 
acid in AD transgenic mice. These data provide further evidence that tolfenamic acid 
could be a promising therapeutic approach as a repurposed AD drug acting through an 
alternative mechanism. 
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Figure II-1. A timeline of tolfenamic acid administration and behavioral 
assessment. Mice were administered tolfenamic acid daily for 34 days. Behavioral 
testing in the Morris water maze began on the 15th day of dosing with daily training 
sessions that lasted until the 23rd day of the study. On the 24th day of dosing, we 
conducted the first session of probe trials (Day 1) and then we performed a second 
session of probe trials on the 34th of dosing (Day 11), to assess for long-term memory 
retention. Trials for the spontaneous alternations in the Y-maze were conducted on the 
33rd day of dosing as well. Animals were euthanized on the 35th day of the study and 
brain tissue was dissected, collected and stored in the -80°C freezer.  
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Figure II-2. Genotyping of in-house bred APP YAC transgenic mice, line R1.40. 
Genetic identification and allelic discrimination was performed using standard 
protocols (see methods section). A) Genetic identification of YAC APP transgenic 
(Tg) and non-transgenic (non-Tg) mice using standard PCR protocol; B) A scatter plot 
of allelic discrimination analysis.  
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Figure II-3. Memory impairments in hemizygous APP YAC transgenic mice, line 
R1.40, assessed by the swimming task in the Morris water maze. A) Acquisition 
patterns during daily training. B) Probe trials for long-term memory retention on Days 
1 and 11 following acquisition-training trials. “*” indicates that the values are 
significantly different from control, as determined by a Student’s t-test (p<0.05).  
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Figure II-4. Working memory impairments in hemizygous APP YAC transgenic 
mice, line R1.40. Mice were examined for working memory function assessed by 
measuring the spontaneous alternation ratio in the Y-maze. “**” indicates that the 
values are significantly different from control, as determined by a Student’s t-test 
(p<0.01)  
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Figure II-5. Effects of the administration of tolfenamic acid to hemizygous APP 
YAC transgenic mice, line R1.40. Tolfenamic acid was administered daily by oral 
gavage for 34 days. See the methods section for details. A) Acquisition patterns during 
daily training trials of 5 mg/kg/day, 50 mg/kg/day and vehicle groups B) Probe trials 
assessing the long-term memory retention on Days 1 and 11 following acquisition-
training trials. “*” indicates that values are significantly different from control, as 
determined by ANOVA analysis with Tukey-Kramer post-hoc test to compare all pairs 
of columns (p<0.05), obtained using GraphPad InStat 3 software. Vehicle n=6; 5 
mg/kg/day n=6; 50 mg/kg/day n=7. 
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Figure II-6. Working memory improvement in hemizygous APP YAC transgenic 
mice, line R1.40, after administration of tolfenamic acid assessed by the 
spontaneous alternations in Y-maze. Tolfenamic acid was administered daily by oral 
gavage for 34 days. See the methods section for details.  “*” indicates that values are 
significantly different from control vehicle, as determined by ANOVA analysis with 
Tukey-Kramer post-hoc test to compare all pairs of columns (p<0.05), obtained using 
GraphPad InStat 3 software. Vehicle n=6; 5 mg/kg/day n=6; 50 mg/kg/day n=7. 
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Figure II-7. Reduction of SP1 protein levels in the brain after treatment with 
tolfenamic acid. Tolfenamic acid was administered daily by oral gavage for 34 days. 
See the methods section for details. A) Western blot analysis of cortical SP1 levels as 
a ratio to the house keeping protein β-actin after treatment with 5 and 50 mg/kg/day of 
tolfenamic acid for 34 days. B) Cortical Sp1 mRNA levels determined by Real-Time 
PCR. “*” indicates that values are significantly different from control, as determined 
by ANOVA analysis with Tukey-Kramer post-hoc test to compare all pairs of columns 
(∗p<0.05, ∗∗p<0.01), obtained using GraphPad InStat 3 software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
 
 
 
 
 
 
79 
 
Figure II-8. Reduction of amyloid precursor protein (APP) levels in the brain 
after treatment with tolfenamic acid. Tolfenamic acid was administered daily by 
oral gavage for 34 days. See the methods section for details. A) Western blot analysis 
of cortical APP levels as a ratio to the house keeping protein β-actin after treatment 
with 5 and 50 mg/kg/day of tolfenamic acid for 34 days. B) Cortical APP mRNA 
determined by Real-Time PCR. “*” indicates that values are significantly different 
from control, as determined by ANOVA analysis with Tukey-Kramer post-hoc test to 
compare all pairs of columns (p<0.05), obtained using GraphPad InStat 3 software.  
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Figure II-9. Reduction of soluble and insoluble Aβ1-40 and Aβ1-42 levels in the 
brain after treatment with tolfenamic acid. Tolfenamic acid was administered daily 
by oral gavage for 34 days. See the methods section for details. Aβ levels were 
quantified by ELISA in the cortices of mice treated with 5 and 50 mg/kg/day of 
tolfenamic acid for 34 days. (A) Soluble Aβ1-40, (B) Insoluble Aβ1-40, (C) Soluble Aβ1-
42 and (D) Insoluble Aβ1-42 levels. “*” indicates that values are significantly different 
from control, as determined ANOVA analysis with Tukey-Kramer post-hoc test to 
compare all pairs of columns (p<0.05), obtained using GraphPad InStat 3 software.  
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ABSTRACT 
BACKGROUND: We have reported that tolfenamic acid treatment decreases 
amyloidogenic proteins in wild type and transgenic mice via lowering of the 
transcription factor specificity 1 protein (Sp1). 
OBJECTIVES: In this study, we examine the ability of tolfenamic acid to reduce the 
amyloid plaque burden in R1.40 mouse model, as well as to ameliorate spatial learning 
and memory deficits in R1.40 and senescent wild type mice.  
METHODS: Behavioral and immunohistochemical analyses were performed 
following the oral administration of multiple doses of tolfenamic acid to homozygous 
R1.40 and senescent wild type mice for 34 days.  
RESULTS: Quantitative immunohistochemical analysis indicated that tolfenamic acid 
treatment resulted in a profound decrease in cerebral amyloid beta (Aβ) plaque burden. 
The reduction in the amyloid pathology was accompanied by improvements in spatial 
working memory assessed by spontaneous alternation ratio in the Y-maze. In addition, 
senescent wild type mice treated with tolfenamic acid exhibited improved spatial 
reference memory performance in the delayed probe trials of the Morris water maze 
compared to the non-treated group.  
CONCLUSION: These results provide further evidence that tolfenamic acid could be 
utilized as a repurposed drug to modify Alzheimer’s disease (AD) pathogenesis.  
Keywords: Alzheimer’s disease; tolfenamic acid; AD transgenic mouse model; 
learning and memory; Morris water maze; Y-maze; immunohistochemistry; amyloid 
plaque burden. 
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1. Introduction 
Alzheimer’s disease (AD) patients suffer from profound general memory loss and 
dementia until death and the disease is known as the most prevalent neurodegenerative 
disorder [1]. Even though Alois Alzheimer has described the disease for more than a 
century, no cure has been discovered yet [2, 3]. Different brain regions especially in 
the cerebral cortex, hippocampus, subcortical nuclei and amygdala suffer extracellular 
senile plaques and intraneuronal neurofibrillary tangles (NFTs) formation that 
characterize the neuropathological deposits identified in AD [2, 4]. Neuritic plaques 
induce the proliferation of astrocytes and microglia with altered morphology leading 
to inflammatory responses that contribute to the brain degeneration observed in the 
disease [5, 6]. 
Senile plaques are mainly composed of aggregated amyloid beta (Aβ) peptides, which 
are 38-43 amino acids long, that are generated by the cleavage of the amyloid 
precursor protein (APP) by the beta-site APP-cleaving enzyme 1 (BACE1) and γ-
secretase [7, 8]. The formation of the insoluble Aβ depositions depends on the rate of 
Aβ production and the rate of its elimination. Thus, the amyloid hypothesis of AD was 
developed, suggesting that amyloid plaque aggregates formed by the amyloidogenic 
breakdown of APP cause the neurodegeneration and dementia seen in AD [9].  
Current FDA approved medications for AD are not disease-modifying therapies and 
do not stop the progression of AD [10]. Tolfenamic acid, a non-steroidal anti-
inflammatory drug (NSAID), induces the degradation of the transcription factor 
specificity protein 1 (Sp1) [11]. Sp1 regulates the expression of several AD-related 
86 
 
genes, and its expression is elevated in the frontal cortex of human AD brains as well 
as in the brains of transgenic mouse models of AD [12, 13]. We have previously 
provided proof-of-concept that tolfenamic acid interrupts the de novo synthesis of APP 
and consequently, alters the downstream levels of Aβ [14]. Treatment of wild type 
C57BL/6 mice with tolfenamic acid lowered the levels of Sp1 protein (SP1) and the 
expression of AD-related Sp1 target genes including APP [14], tau and BACE1 
(unpublished observations), and was supported by measurements which demonstrated 
the presence of tolfenamic acid in the brain following IV administration [15]. In 
addition, data from our lab showed that tolfenamic acid reversed the cognitive deficits 
in the hemizygous R1.40 transgenic mouse model of AD and lowered the levels of 
SP1, APP and soluble and insoluble Aβ1–40 and Aβ1–42.  
The purpose of the current study was to investigate the ability of tolfenamic acid to 
lower Aβ plaque load in old homozygous R1.40 mice that exhibit fibrillar plaque 
depositions between the ages of 14 and 15 months [16, 17]. Furthermore, we 
investigated if tolfenamic acid would ameliorate the cognitive impairments even long 
after plaque deposition has begun in homozygous R1.40 mice. In addition, we also 
administered tolfenamic acid to senescent wild type mice to determine whether the 
treatment could enhance their mnemonic functions as they express age-related spatial 
working and reference memory decline in the absence of plaque deposition. 
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2. Methods 
2.1. Animal model  
Wild type mice and a genomic-based transgenic mouse model, R1.40, were utilized 
for this study. The transgenic mice, developed by Bruce T. Lamb, were obtained from 
the Jackson laboratory (Bar Harbor, ME, USA) and colonies of homozygous strains 
were established in-house. The R1.40 mouse model utilizes a yeast artificial 
chromosome (YAC) that includes the full 400 kb human APP gene and the flanking 
sequence of approximately 250 kb to harbor the Swedish mutation 
APPK670N/M671L and human transcriptional regulatory elements, allowing for 
proper spatial and temporal expression [18-20]. The mnemonic deficits in 
homozygous R1.40 are similar to those observed in AD and the model shows a great 
increase in APP and Aβ production with Aβ deposition occurring at 14-15 months of 
age compared to the wild type [21, 22].  
Mice colonies were established in-house at the University of Rhode Island (URI) 
animal quarter facility. Mice were bred and genotyped using two genotyping 
techniques including standard PCR followed by gel electrophoresis, and was 
confirmed using the TaqMan® allelic discrimination assay (Applied Biosystems, 
Foster City, CA, USA). Mice of different genotypes were housed in standard mouse 
cages in rooms with temperature maintained at 22±2°C with humidity levels of 
55±5%. The rooms were set for 12:12 hr light-dark cycle (light on 6:00 AM, light off 
at 6:00 PM) and the animals were provided with food and water ad libitum. A URI 
veterinarian continuously supervised the animals during the entire period of the study 
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and assisted in drug administration. All the protocols including breeding and 
genotyping techniques were approved by the URI Institutional Animal Care and Use 
Committee (IACUC).  
2.2. Animal exposure to tolfenamic acid and behavioral testing 
Tolfenamic acid was obtained from Sigma Aldrich (St. Louis, MO, USA) and 
homozygous APP YAC transgenic mice of mixed gender aging between 19-24 months 
were used to examine the ability of the drug to reduce the amyloidogenic plaque load 
and to improve the learning and memory deficits observed in these mice. The animals 
were divided into three groups of similar age and gender variation and were 
administered tolfenamic acid daily via oral gavage for 34 days; one group was 
administered 5 mg/kg/day tolfenamic acid in corn oil (n=7); the second group was 
administered 50 mg/kg/day tolfenamic acid in corn oil (n=6) and the third group was 
administered corn oil, the vehicle, (n=7). In addition, tolfenamic acid was 
administered to old wild type mice of mixed gender aging between 18-24 months in 
order to study its effects on learning and memory. The animals were divided into three 
groups of similar age and gender variation and were administered tolfenamic acid 
daily via oral gavage for 34 days; one group was administered 5 mg/kg/day tolfenamic 
acid in corn oil (n=11); the second group was administered 50 mg/kg/day tolfenamic 
acid in corn oil (n=10) and the third group was administered corn oil, the vehicle, 
(n=13). 
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2.3. Assessment of cognitive functions following tolfenamic acid treatment in 
homozygous R1.40 transgenic mice and wild type mice  
Memory and cognitive functions in homozygous R1.40 transgenic and wild type mice 
were characterized through behavioral testing in mazes that examine the integrity of 
the hippocampus and the brain cortex including the Morris water maze and 
spontaneous alternations in the Y-maze. After 14 days of daily dosing, testing began in 
the Morris water maze and on Day 33 mice were tested for spontaneous alternations in 
Y-maze. Finally, on Day 35, mice were euthanized and brains were extracted. 
2.3.1. Morris water maze 
Mice were tested in the hidden version of the Morris water maze where they had to 
locate a hidden platform by learning multiple spatial relationships between the 
platform and the distal extra-maze cues [23-25]. The apparatus consisted of a white 
48” diameter pool that is 30” in height and was filled with water to a depth of 14”. 
Non-toxic washable liquid paint was added to the water to keep it opaque. Distinct 
fixed visual cues surrounded the pool that the animals used for navigation while 
trying to reach the escape platform. A clear Plexiglas platform square of 10 cm was 
kept submerged 0.5 cm below the surface of the water. The temperature of the water 
was always kept around 25 ±2°C during all procedures in the water maze.  
Habituation trial in which mice were allowed to swim freely for 60 sec to acclimate 
to the procedure was conducted on Day 15 of drug administration. On the following 
day and for a total of 8 days, mice received training sessions of three trials daily. For 
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each trial, the starting position was randomly assigned between the four possible 
positions while the platform position was kept the same for the entire training 
sessions.  
Each animal was allowed to swim until it found the immersed hidden platform or for 
a maximum duration of 60 sec. A mouse that failed to locate the platform in the first 
60 sec would be gently guided to sit on the platform for a maximum duration of 30 
sec. Upon a successful trial, the mouse would be left to sit on the platform for a 
maximum of 10 sec. Following conducting the eight acquisition sessions, probe 
trials for up to 60 sec on Day 1 and Day 11 following the last day of training were 
performed to assess the long-term memory retention. This was achieved by studying 
the preference of the mice to swim in the correct quadrant that previously contained 
the hidden platform. All trials including the swim paths and latencies to locate the 
platform were videotaped and tracked with a computerized video tracking system 
(ObjectScan, Clever Sys. Inc., Reston, VA, USA) and the resultant data were 
analyzed. 
2.3.2. Spontaneous alternations in the Y-maze  
The spontaneous alternation ratio, defined as the percentage of the number of arm 
entries, different from the previous two entries, divided by the total arm entries 
minus two was measured [22, 26]. Testing trials were conducted in a white Y-maze 
with arms that were 12” (long) by 3” (wide) with 8” height walls. Mice were placed 
into one of the Y-maze arms and were left to explore the maze freely for 5 minutes. 
After each trial, the maze was cleaned with 70% ethanol. Y-maze trials were 
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videotaped and tracked with a computerized video tracking system (ObjectScan, 
Clever Sys. Inc., Reston, VA, USA) and the data were analyzed. 
2.4.  Tissue preparation 
Following 34 days of daily administration of tolfenamic acid and on Day 35, 
homozygous R1.40 mice were deeply anesthetized with an intraperitoneal injection of 
0.1 ml/10g of xylazine-ketamine mixture (100 mg/ml-10 mg/ml) and were perfused 
transcardially with 100 ml of perfusion wash that consisted of 0.8% sodium chloride, 
0.8% sucrose, 0.4% dextrose, 0.034% anhydrous sodium cacodylate and 0.023% 
calcium chloride. After that, mice were perfused with 100 ml of perfusion fix that 
consisted of 4% paraformaldehyde, 4% sucrose and 1.07% anhydrous sodium 
cacodylate and the brains were removed. The extracted brains were post-fixed in the 
perfusion fix solution overnight and then they were cryopreserved in 30% sucrose 
solution. Fixed brains were subject to coronal sectioning (40 µm) and collection using 
MultiBrain® Technology (NeuroScience Associates, Knoxville, TN, USA) and 
sections were stored in preservative fix at -20°C. MultiBrain® Technology allows 
brains from different groups to be embedded together in the solid matrix and to be 
processed as a single unit. That enabled treatment of different brain sections under the 
same conditions providing more built-in quality control leading to obtaining uniform 
staining.  For the wild type group, on Day 35, the mice were anesthetized with carbon 
dioxide, euthanized and their brains were extracted and stored at -80°C. 
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2.5. Immunohistochemistry 
To identify and quantify amyloid plaques in brain sections from different groups, free-
floating sections were taken from the preservative solution and were washed with 
distilled water. That was followed by washing with 1X phosphate buffer saline (PBS) 
three times, three min each. After that, sections were immersed in a solution of 3% 
hydrogen peroxide (H2O2) for 30 min to quench the endogenous peroxidase activity. 
Sections were rinsed three times with PBS for three min each and then incubated in 
70% formic acid solution for 30 min at room temperature. The sections were washed 
with PBS three times, three min each and were incubated in 3% bovine serum albumin 
(BSA) and 0.1% Triton X-100 for 30 min. After rinsing with PBS, sections were 
Incubated with 1 antibody against Aβ (6E10, Sig-39320, Covance, Dedham, MA, 
USA) of 1:200 dilution overnight at 4°C. That was followed by incubation with the 
appropriate species-specific biotinylated secondary antibody (Vector Labs, 
Burlingame, CA, USA) of 1:500 dilution for 30 min and then the sections were 
incubated with horseradish peroxidase HRP-conjugated streptavidin (Vector Labs, 
Burlingame, CA, USA) for 30 min. After that, sections were washed with PBS and the 
immunoreactivity was detected and visualized with the substrate 3-3, 
diaminobenzidine (DAB) (Vector Labs, Burlingame, CA, USA). Brain sections were 
counterstained with hematoxylin. The sections were mounted on microscope slides 
according to procedure provided by NeuroScience Associates and coverslips were 
mounted with permanent mounting medium (Vector Labs, Burlingame, CA, USA). 
93 
 
2.6. Quantification of Aβ plaques 
Evaluation of the extracellular Aβ plaque load in the cerebral cortex was performed 
using a Nikon Eclipse E600 microscope (Nikon, Melville, NY, USA) attached with a 
Diagnostic Instruments digital camera and using SPOT Diagnostic Instruments 
software (Diagnostic Instruments, Sterling Heights, MI, USA). Serial images of 10X 
magnification were captured on four sections per animal that were 80 µm apart from 
each other. Using ImageJ software from NIH (Bethesda, MD, USA), the images were 
binarized to 16-bit grey scale and were segmented to distinguish the aggregates from 
background. The minimum and maximum size was set to exclude objects in the image 
that were clearly not of interest and data were collected including size, number and 
area of the plaques. Amyloid burden was expressed as the percent area stained positive 
for Aβ to the total area analyzed.  
2.7.  Statistical analysis  
The significance of difference between different treatment groups was determined 
by repeated measure analysis of variance (ANOVA) and Tukey-Kramer multiple 
comparison post-hoc test. Data are expressed as the mean ± the standard error of the 
mean (SEM). All statistical analyses were conducted using GraphPad InStat 3 
software (GraphPad Software, La Jolla, CA, USA)and probability (p) value of <0.05 
was considered acceptable for statistical significance.  
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Results 
3.1. Treatment with tolfenamic acid attenuates the cognitive deficits in homozygous 
R1.40 mouse model  
We examined the effects of tolfenamic acid treatment of 5 and 50 mg/kg/day on 
learning and memory in groups of old homozygous R1.40 transgenic mice aging 
between 19-24 months. There was a significant effect of training as ANOVA analysis 
showed that the difference in escape latency between the first and the last day of 
training sessions was statistically significant (F(7,152) = 7.293, p < 0.0001). The 
results showed that in the Morris water maze, the difference in the escape latency 
during the training phase between different experimental groups was not statistically 
significant. However, the tolfenamic acid treated groups showed a trend of better 
performance than the control vehicle group through days 4-8 of the training sessions 
(Fig. 1A). Analysis of probe trials Day 1 and Day 11 indicated that while both 
tolfenamic acid treatment groups scored higher percentages in the correct quadrant 
than the control group in both probe trials, the difference was not statistically 
significant (p ≥ 0.05) (Fig. 1B).  
Nevertheless, results from repeated measures ANOVA analysis of the spontaneous 
alternation ratio in the Y-maze showed a significantly improved working memory 
function (F(2,14) = 4.495, p = 0.0311) (Fig. 2). The Tukey-Kramer HSD post-hoc test 
indicated a significant effect of 50 mg/kg/day tolfenamic acid treatment in improving 
spatial working memory (HSD = 3.702, p < 0.05), while the treatment with 5 
mg/kg/day did not reach significance (HSD = 0.91, p ≥ 0.05) (Fig. 2). 
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3.2. Effects of tolfenamic acid treatment on spatial learning and memory in old wild 
type mice  
Several studies have reported age-related spatial memory impairments and thus we 
wanted to examine whether tolfenamic acid treatment could alter learning and memory 
in old C57BL/6 mice. Again, there was a significant effect of training as ANOVA 
analysis showed that the difference in escape latency between the first to the last daily 
training sessions was statistically significant (F(7,264) = 8.858, p < 0.0001) (Fig. 3A). 
Our results showed that in the Morris water maze task, the escape latency during the 
training phase of the different experimental groups was not statistically significant. 
However, repeated measures ANOVA analysis of probe trial Day 11 revealed a 
significant improvement in the spatial reference memory function (F(2,29) = 4.811, p 
= 0.0291) (Fig. 3B). The Tukey-Kramer HSD post-hoc test showed that mice group 
treated with 5 mg/kg/day tolfenamic acid dose had a significant improvement (HSD = 
3.828, p < 0.05) while difference in percent time mice spent in the correct quadrant 
after treatment with 50 mg/kg/day versus the control group did not reach statistical 
significance (HSD = 2.632, p ≥ 0.5) (Fig. 3B).  
In the Y-maze, ANOVA analysis of spontaneous alternation ratio did not indicate a 
significant difference between different treatment groups (F(2,30) = 0.451, p = 0.641) 
(Fig. 4). 
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3.3. Tolfenamic acid treatment significantly reduces Aβ amyloid deposition in aged 
homozygous R1.40 mice 
As described in the literature, the homozygous R1.40 mouse model develops 
extracellular Aβ plaques that start to be evident between the ages of 14 and 15 months 
[16, 17]. Tolfenamic acid treatment with both doses greatly reduced amyloid plaque 
pathology in multiple cerebral cortical regions such as the primary somatosensory 
cortex, parietal association cortex, auditory cortex and insular cortex, compared to 
non-treated mice (Fig. 5A). Quantitative immunohistochemistry analysis revealed that 
tolfenamic acid treatment for 34 days significantly lowered Aβ plaque deposition 
F(2,14) = 6.685, p = 0.009) (Fig. 5B). The Tukey-Kramer HSD post-hoc test indicated 
that 5 and 50 mg/kg/day tolfenamic acid doses lowered amyloid deposition 
significantly (HSD = 3.779, p < 0.05 and HSD = 5.012 p < 0.01, respectively) (Fig. 
5B). Consistent with previously reported data describing the pathology and the 
behavioral deficits in homozygous R1.40 [22], there was no correlation between the 
extent of Aβ deposition and the time spent in the correct quadrant during the probe 
trials conducted in Day 1 and Day 11 following the training sessions (Day 1 retention, 
r(17) = 0.049, p > 0.1; Day 11 retention, r(17) = -0.113, p > 0.1). However, there was 
a significant correlation between the plaque burden and the spontaneous alternation 
ratio (r(17) = -0.482, p = 0.042). 
3. Discussion  
Certain NSAIDs have been shown to alter AD pathology and attenuate learning and 
memory deficits in murine mouse models of AD by mechanisms other than their 
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classic cyclooxygenase (COX) inhibition pathway and have led researchers to 
consider such NSAIDs as potential disease-modifying agents for AD [27-29]. 
Tolfenamic acid, of all other NSAIDs, has the unique mechanism of inducing the 
proteasome-dependent degradation of SP transcription factors including SP1, SP3 and 
SP4 and thereby, decreasing the expression of the vascular endothelial growth factors 
(VEGF), which is involved in tumor progression and metastases [11]. Elevated levels 
of Sp1 have been found in the frontal cortex of the brains of AD patients as well as in 
the brains of transgenic mouse models of AD [12, 13]. Interplay between 
inflammatory processes and Sp1-driven gene expression has been suggested, as the 
elevation of Sp1 was accompanied by an increase in COX-2 expression, an Sp1 target 
gene [12].  
Sp1 induces the expression of genes involved in AD pathology which include APP, 
BACE1 and tau as their promoter regions are rich with 5’-GGGGCGGGGC- sequence 
that Sp1 binds to [12, 30, 31]. Thus, we hypothesized and we showed that tolfenamic 
acid could interrupt the de novo synthesis of APP and alter the downstream levels of 
Aβ in C57BL/6 mice [14] and hemizygous R1.40 transgenics leading to improvements 
in learning and memory profiles.  
As a genomic-based transgenic mouse model of AD, R1.40 line represents a valuable 
tool for assessing the effects of potential AD therapeutics in reducing amyloidogenic 
pathology and in improving learning and memory profiles. At 14-15 months of age, 
homozygous R1.40 mice exhibit depositions of extracellular Aβ plaques accompanied 
by cognitive deficits [16, 17, 22]. The mice demonstrate the ability to learn the 
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location of the hidden platform during daily training session trials in the Morris water 
maze; however, they exhibit a decline in long-term memory retention compared to 
non-transgenic mice as assessed by probe trials. In addition, when these mice were 
assessed for the spontaneous alternation ratio in the Y-maze, impairments in the 
working memory functions were observed [22].  
The present study provides the first evidence of the ability of a relatively short-term 
tolfenamic acid treatment to reduce Aβ plaque burden drastically in homozygous 
R1.40 compared to longer treatments for 6-9 months in other transgenic models with 
another NSAID, namely ibuprofen [32, 33]. It was also observed that tolfenamic acid 
treatment results in a greater lowering of Aβ peptide levels in wild type C57BL/6 and 
hemizygous R1.40 mice compared to the reduction of APP ([14]; unpublished data), 
indicating that additional mechanisms responsible for plaque degradation and 
clearance of Aβ are involved.  
We also examined the ability of tolfenamic acid treatment to attenuate the spatial 
memory deficits observed in old homozygous R1.40 mice aging between 19-24 
months, which have been suffering from Aβ plaque deposition reported to start as 
early as 14 months of age [21]. We found that both doses of 5 and 50 mg/kg/day 
resulted in a trend of shorter latency during daily Morris water maze training trials and 
higher percentage in the correct quadrant during both probe trials compared to the 
vehicle treated group. However, those differences from the vehicle treated group did 
not reach statistical significance.  
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We exposed animals to tolfenamic acid at senescence whilst the combined effect of 
age and the mutant transgene persisted. Thus, lowering the amyloidogenic pathology 
may not have been sufficient enough to retrieve enough spatial reference memory 
capabilities to perform significantly well in the Morris water maze compared to the 
non-treated group. At the onset of tolfenamic acid exposure, the extensive plaque 
pathology in different cortical regions has been in effect for a long period of time. It is 
well known that Aβ plaques are toxic, affect synaptic plasticity, and stimulate the 
production of reactive oxygen species (ROS) leading to elevations in the oxidative 
stress and neuronal cell death. It is possible that the damage by Aβ deposition on 
memory networks was extensive and irreversible by the time treatment started, even 
though tolfenamic acid treatment reduced the plaque burden significantly.  
Alternatively, there may be a lesser connection between spatial memory functions and 
the plaque burden. The previous explanation is supported by the fact that tolfenamic 
acid significantly improved mice performance in the spontaneous alternations in the 
Y-maze. The spontaneous alternations task is mainly dependent on the hippocampus 
and the prefrontal cortex [34], and as described in the literature, R1.40 mice only show 
scattered Aβ plaque deposition in hippocampal formation [16, 22] which is in 
consistency with our observations (data not shown).  
In aged wild type C57BL/6 mice, short-term tolfenamic acid administration was able 
to improve certain spatial mnemonic deficits. Data analysis of Morris water maze 
probe trial in Day 11 shows that tolfenamic acid significantly improved spatial 
reference memory while there was no effect in improving the spatial working memory 
100 
 
assessed by spontaneous alternations in the Y-maze. Wild type mice do not develop 
amyloid plaque pathology, however, tolfenamic acid reduces APP and Aβ levels in 
C57BL/6 mice [14]. It is not clear if the improved spatial reference memory was due 
to the reduction of Aβ levels or due to tolfenamic acid’s effects on other pathways 
mediated by COX inhibition or by non-COX effects.  
We have found that Aβ levels in hippocampus were lowered by tolfenamic acid [14], 
however, spontaneous alternation ratio was not altered by tolfenamic acid treatment. It 
is possible that non-amyloidogenic processes that are not altered by tolfenamic acid 
treatment are contributing strongly to the age-related spatial working memory 
impairments in C57BL/6 mice. For example, those deficits were explained as due to 
alterations in the synaptic plasticity within the hippocampal formation [35] that were 
attributed to changes in the functional properties of NMDA receptors and changes in 
calcium homeostasis [36-38]. Fordyce and Wehner suggested that reduction in the 
activity membrane-bound protein kinase C (PKC) in the hippocampus was associated 
with the age-related decline in spatial learning and memory [39]. In addition, the 
increase in reactive oxygen species (ROS) and brain oxidative stress is another 
mechanism involved in age-related behavioral deficits [40, 41]. Furthermore, it has 
been reported that hippocampal glucose levels depletion contributes to memory 
dysfunction, and that systemic glucose administration reverses the age-dependent 
decrease in the spontaneous alternation ratio [42, 43].   
Consistent with our prior findings in hemizygous R1.40 mice, the present study 
indicates that tolfenamic acid is effective in lowering the amyloidogenic proteins and 
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Aβ plaques with both doses, with dose-dependent improvements in cognitive deficits. 
We still have to study the effects of extended period of tolfenamic acid exposure with 
low doses as it may result in significant improvements in cognitive functions. It is 
essential to mention that compared to other FDA approved AD drugs and NSAIDs, 
tolfenamic acid significantly decreased plaque pathology and produced significant 
behavioral improvements in a relatively short duration of treatment. For example, 0.58 
mg/kg/day donepezil, an FDA-approved anticholinesterase drug for AD, improved 
performance in the Morris water maze after two months of treatment in APP23 
transgenic mice [44]. Another FDA-approved drug for use in moderate to severe AD, 
memantine, improved cognition in 3x TG-AD mice after three months of treatment 
[45]. In addition, ibuprofen was able to produce improvement in cognitive functions in 
triple transgenic mice (APPswe, PS1M146V and tauP301L) following its 
administration for six months [46]. 
In conclusion, we report that tolfenamic acid treatment drastically reduces Aβ plaque 
pathology that is accompanied by improvement in spatial learning and memory in a 
murine mouse model of AD. This occurs within a period that is much shorter than that 
observed with other NSAIDs. Our data suggest that tolfenamic acid treatment can also 
combat certain age-related mnemonic deficits in wild type mice. The data provide 
further evidence of the ability of tolfenamic acid, through Sp1 reduction, to disrupt the 
development and the progression of the pathological processes of AD. Thus, 
tolfenamic acid, as a repurposed AD drug, could be a promising disease-modifying 
therapeutic agent acting through an alternative mechanism. 
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Figure III-1. Effects of tolfenamic acid on spatial reference memory in 
homozygous R1.40 mice. Tolfenamic acid was administered by oral gavage daily for 
34 days and behavioral testing was conducted in the Morris water maze. See the 
methods section for details. A) Acquisition patterns during daily training trials for the 
5 mg/kg/day, 50 mg/kg/day and vehicle groups; B) Probe trials assessing the long-
term memory retention on Days 1 and 11 following acquisition training trials. Data 
were analyzed by ANOVA with Tukey-Kramer post-hoc test to compare all pairs of 
columns, obtained using GraphPad InStat 3 software. Vehicle n=7; 5 mg/kg/day n=7; 
50 mg/kg/day n=6.  
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Figure III-2. Working memory improvement in homozygous R1.40 transgenic 
mice after administration of tolfenamic acid. Tolfenamic acid was administered by 
oral gavage daily for 34 days. Working memory was assessed by spontaneous 
alternations in the Y-maze. See the methods section for details. “*” indicates that 
values are significantly different from control vehicle, as determined by ANOVA 
analysis with Tukey-Kramer post-hoc test to compare all pairs of columns (p<0.05), 
obtained using GraphPad InStat 3 software. Vehicle n=7; 5 mg/kg/day n=7; 50 
mg/kg/day n=6.  
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Figure III-3. Administration of tolfenamic acid to old wild type mice alters 
spatial reference memory. Tolfenamic acid was administered by oral gavage daily 
for 34 days. Spatial reference memory was tested in the Morris water maze. See the 
methods section for details. A) Acquisition patterns during daily training trials for the 
5 mg/kg/day, 50 mg/kg/day and vehicle groups. B) Probe trials assessing the long-
term memory retention on Days 1 and 11 following acquisition training trials. “*” 
indicates that values are significantly different from control, as determined by 
ANOVA analysis with Tukey-Kramer post-hoc test to compare all pairs of columns 
(p<0.05), obtained using GraphPad InStat 3 software. Vehicle n=13; 5 mg/kg/day 
n=11; 50 mg/kg/day n=10.  
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Figure III-4. Performance of old wild type mice in the Y-maze following 
administration of tolfenamic acid. Tolfenamic acid was administered by oral gavage 
daily for 34 days. See the methods section for details. Vehicle n=13; 5 mg/kg/day 
n=11; 50 mg/kg/day n=10.  
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Figure III-5. Treatment with tolfenamic acid reduces cortical Aβ plaque burden 
in homozygous R1.40 mice. Tolfenamic acid was administered by oral gavage daily 
for 34 days. See the methods section for details. A) Represents images of Aβ plaque 
morphology and density in the cerebral cortex in different treatment groups after 
immunohistochemical staining against Aβ using 6E10 antibody. CT TG = control 
transgenic B) Quantification of total Aβ plaque area. “*” indicates that values are 
significantly different from control, as determined by ANOVA analysis with Tukey-
Kramer post-hoc test to compare all pairs of columns (∗p<0.05, ∗∗p<0.01), obtained 
using GraphPad InStat 3 software. Vehicle n=5; 5 mg/kg/day n=7; 50 mg/kg/day n=5.  
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